Vaccine exemptions and the kindergarten vaccination coverage gap

Vaccine
Volume 35, Issue 40, Pages 5309-5434 (25 September 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/40?sdc=1

Original Research Article
Vaccine exemptions and the kindergarten vaccination coverage gap
Original Research Article
Pages 5346-5351
Philip J. Smith, Jana Shaw, Ranee Seither, Adriana Lopez, Holly A. Hill, Mike Underwood, Cynthia Knighton, Zhen Zhao, Megha Shah Ravanam, Stacie Greby, Walter A. Orenstein
Abstract
Background
Vaccination requirements for kindergarten entry vary by state, but all states require 2 doses of measles containing vaccine (MCV) at kindergarten entry.
Objective
To assess (i) national MCV vaccination coverage for children who had attended kindergarten; (ii) the extent to which undervaccination after kindergarten entry is attributable to parents’ requests for an exemption; (iii) the extent to which undervaccinated children had missed opportunities to be administered missing vaccine doses among children whose parent did not request an exemption; and (iv) the vaccination coverage gap between the “highest achievable” MCV coverage and actual MCV coverage among children who had attended kindergarten.
Methods
A national survey of 1465 parents of 5–7 year-old children was conducted during October 2013 through March 2014. Vaccination coverage estimates are based provider-reported vaccination histories. Children have a “missed opportunity” for MCV if they were not up-to-date and if there were dates on which other vaccines were administered but not MCV. The “highest achievable” MCV vaccination coverage rate is 100% minus the sum of the percentages of (i) undervaccinated children with parents who requested an exemption; and (ii) undervaccinated children with parents who did not request an exemption and whose vaccination statuses were assessed during a kindergarten grace period or period when they were provisionally enrolled in kindergarten.
Results
Among all children undervaccinated for MCV, 2.7% were attributable to having a parent who requested an exemption. Among children who were undervaccinated for MCV and whose parent did not request an exemption, 41.6% had a missed opportunity for MCV. The highest achievable MCV coverage was 98.6%, actual MCV coverage was 90.9%, and the kindergarten vaccination gap was 7.7%.
Conclusion
Vaccination coverage may be increased by schools fully implementing state kindergarten vaccination laws, and by providers assessing children’s vaccination status at every clinic visit, and administering missed vaccine doses.

Intention to accept pertussis vaccine among pregnant women in Karachi, Pakistan

Vaccine
Volume 35, Issue 40, Pages 5309-5434 (25 September 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/40?sdc=1

Intention to accept pertussis vaccine among pregnant women in Karachi, Pakistan
Original Research Article
Pages 5352-5359
Mariam Siddiqui, Afshin Alaf Khan, Aiden Kennedy Varan, Alejandra Esteves-Jaramillo, Shazia Sultana, Asad S. Ali, Anita K.M. Zaidi, Saad B. Omer
Abstract
Background
Maternal immunization against pertussis is a potential strategy to protect young infants from severe disease. We assessed factors associated with intention to accept pertussis vaccination among pregnant women in Karachi, Pakistan.
Methods
We conducted a cross-sectional survey between May and August 2013 in pregnant women who visited healthcare centers in urban slums of Karachi city. Women completed a survey examining socio-demographic factors, vaccination history, knowledge on pertussis disease, perception of vaccine recommendation sources, and potential influences on vaccine decision-making.
Results
Of the 283 participants, 259 (92%) provided their intention to either accept or decline pertussis vaccination. Eighty-three percent women were willing to accept the pertussis vaccine if offered during pregnancy. About half (53%) of the participants had ever heard of pertussis disease. Perceptions of pertussis vaccine efficacy, safety, and disease susceptibility were strongly associated with intention to accept pertussis vaccine (p < 0.01). Healthcare providers, Ministry of Health, and mass media were considered as highly reliable sources of vaccine recommendation and associated with intention to accept antenatal pertussis vaccination (p < 0.001). Healthcare provider recommendation was a common reason cited by respondents for pregnant women to accept antenatal pertussis vaccination (p = 0.0005). However, opinion of primary decision-makers in the family (husbands and in-laws) was a crucial reason cited by respondents for pregnant women to reject pertussis vaccination in pregnancy (p = 0.003).
Conclusion
Antenatal pertussis vaccination initiatives in South Asia should strongly consider inclusion of family members, healthcare providers, national health ministries, and mass media to help implement new vaccination programs.

Advancing new vaccines against pandemic influenza in low-resource countries

Vaccine
Volume 35, Issue 40, Pages 5309-5434 (25 September 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/40?sdc=1

Special Section on “World Vaccine Congress Series Papers”; Edited by T. Kaser
Advancing new vaccines against pandemic influenza in low-resource countries
Original Research Article
Pages 5397-5402
Francesco Berlanda Scorza

Developing and financing neglected disease vaccines in our new era of “blue marble health” and the anthropocene epoch

Vaccine
Volume 35, Issue 40, Pages 5309-5434 (25 September 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/40?sdc=1

Developing and financing neglected disease vaccines in our new era of “blue marble health” and the anthropocene epoch
Pages 5403-5405
Peter J. Hotez
Abstract
New findings of widespread neglected diseases among the poor living in wealthy group of 20 (G20) economies and the concept of “blue marble health” offer innovative mechanisms for financing urgently new vaccines, especially for vector-borne neglected tropical diseases (NTDs). This approach could complement or parallel a recently suggested global vaccine development fund for pandemic threats.
 

Current Status of Rift Valley Fever Vaccine Development

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines
(Accessed 23 September 2017)

Review
Current Status of Rift Valley Fever Vaccine Development
by Bonto Faburay, Angelle Desiree LaBeaud, D. Scott McVey, William C. Wilson and Juergen A. Richt
Vaccines 2017, 5(3), 29; doi:10.3390/vaccines5030029 – 19 September 2017
Abstract
Rift Valley Fever (RVF) is a mosquito-borne zoonotic disease that presents a substantial threat to human and public health. It is caused by Rift Valley fever phlebovirus (RVFV), which belongs to the genus Phlebovirus and the family Phenuiviridae within the order Bunyavirales. The wide distribution of competent vectors in non-endemic areas coupled with global climate change poses a significant threat of the transboundary spread of RVFV. In the last decade, an improved understanding of the molecular biology of RVFV has facilitated significant progress in the development of novel vaccines, including DIVA (differentiating infected from vaccinated animals) vaccines. Despite these advances, there is no fully licensed vaccine for veterinary or human use available in non-endemic countries, whereas in endemic countries, there is no clear policy or practice of routine/strategic livestock vaccinations as a preventive or mitigating strategy against potential RVF disease outbreaks. The purpose of this review was to provide an update on the status of RVF vaccine development and provide perspectives on the best strategies for disease control. Herein, we argue that the routine or strategic vaccination of livestock could be the best control approach for preventing the outbreak and spread of future disease

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Current Topics in Microbiology and Immunology
Springer, Berlin, Heidelberg  2017
Accelerating Vaccine Development During the 2013–2016 West African Ebola Virus Disease Outbreak
Elizabeth S. Higgs, Sheri A. Dubey, Beth A. G. Coller, Jakub K. Simon, Laura Bollinger, Robert A. Sorenson, Barthalomew Wilson, Martha C. Nason, Lisa E. Hensley
First Online: 17 September 2017
Abstract
The Ebola virus disease outbreak that began in Western Africa in December 2013 was unprecedented in both scope and spread, and the global response was slower and less coherent than was optimal given the scale and pace of the epidemic. Past experience with limited localized outbreaks, lack of licensed medical countermeasures, reluctance by first responders to direct scarce resources to clinical research, community resistance to outside interventions, and lack of local infrastructure were among the factors delaying clinical research during the outbreak. Despite these hurdles, the global health community succeeded in accelerating Ebola virus vaccine development, in a 5-month interval initiating phase I trials in humans in September 2014 and initiating phase II/III trails in February 2015. Each of the three Ebola virus disease-affected countries, Sierra Leone, Guinea, and Liberia, conducted a phase II/III Ebola virus vaccine trial. Only one of these trials evaluating recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein demonstrated vaccine efficacy using an innovative mobile ring vaccination trial design based on a ring vaccination strategy responsible for eradicating smallpox that reached areas of new outbreaks. Thoughtful and intensive community engagement in each country enabled the critical community partnership and acceptance of the phase II/III in each country. Due to the delayed clinical trial initiation, relative to the epidemiologic peak of the outbreak in the three countries, vaccine interventions may or may not have played a major role in bringing the epidemic under control. Having demonstrated that clinical trials can be performed during a large outbreak, the global research community can now build on the experience to implement trials more rapidly and efficiently in future outbreaks. Incorporating clinical research needs into planning for future health emergencies and understanding what kind of trial designs is needed for reliable results in an epidemic of limited duration should improve global response to future infectious disease outbreaks.
 
 
Gynecologic Oncology
Volume 147, Issue 1, October 2017, Pages 209-210
Racial Differences in Reasons for Lack of HPV Vaccine Initiation in Adolescent Girls in the US, 2015
A Beavis, M Krakow, K Levinson, A Rositch – Gynecologic Oncology, 2017
Objectives: While cervical cancer rates are higher in black compared to white women, HPV vaccine initiation is lower in white teens compared to black teens. We sought to characterize differences in reasons for non-initiation of the HPV vaccine between parents of black and white adolescent females in 2015.

Awareness of HPV Vaccinations and Barriers to Vaccination Administration Among Underserved Women
R Guerra, A Bhalwal, C Ibarra, N Jooya, SC Robazetti… – Gynecologic Oncology, 2017
Objectives: To delineate awareness and knowledge of HPV vaccinations among medically underserved women who attend health fairs and identify barriers to vaccine administration.

Brain, Behavior, and Immunity
Available online 17 September 2017
Positive Mood on the Day of Influenza Vaccination Predicts Vaccine Effectiveness: A Prospective Observational Cohort Study
K Ayling, L Fairclough, P Tighe, I Todd, V Halliday…
Abstract
Influenza vaccination is estimated to only be effective in 17–53% of older adults. Multiple patient behaviors and psychological factors have been shown to act as ‘immune modulators’ sufficient to influence vaccination outcomes. However, the relative importance of such factors is unknown as they have typically been examined in isolation. The objective of the present study was to explore the effects of multiple behavioral (physical activity, nutrition, sleep) and psychological influences (stress, positive mood, negative mood) on the effectiveness of the immune response to influenza vaccination in the elderly. A prospective, diary-based longitudinal observational cohort study was conducted. One hundred and thirty-eight community-dwelling older adults (65–85 years) who received the 2014/15 influenza vaccination completed repeated psycho-behavioral measures over the two weeks prior, and four weeks following influenza vaccination. IgG responses to vaccination were measured via antigen microarray and seroprotection via hemagglutination inhibition assays at 4 and 16 weeks post-vaccination. High pre-vaccination seroprotection levels were observed for H3N2 and B viral strains. Positive mood on the day of vaccination was a significant predictor of H1N1 seroprotection at 16 weeks post-vaccination and IgG responses to vaccination at 4 and 16 weeks post-vaccination, controlling for age and gender. Positive mood across the 6-week observation period was also significantly associated with post-vaccination H1N1 seroprotection and IgG responses to vaccination at 16 weeks post-vaccination, but in regression models the proportion of variance explained was lower than for positive mood on the day of vaccination alone. No other factors were found to significantly predict antibody responses to vaccination. Greater positive mood in older adults, particularly on the day of vaccination, is associated with enhanced responses to vaccination.

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

New York Times
http://www.nytimes.com/
Accessed 23 September 2017
The HPV Vaccine Gains Ground Among U.S. Teenagers
Sixty percent of adolescents received the vaccine in 2016. A decade ago, less than 30 percent did.
September 22, 2017 – By ANERI PATTANI

Superbug’s Spread to Vietnam Threatens Malaria Control
Vietnam’s main malaria treatment is failing at an alarming rate because of a highly drug-resistant superbug that has spread into the southern part of the country from western Cambodia, scientists said Thursday.
September 21, 2017 – By THE ASSOCIATED PRESS

Washington Post
http://www.washingtonpost.com/
Accessed 23 September 2017
Europe
Greece makes measles vaccination appeal amid European spike
By Associated Press September 22
ATHENS, Greece — Health authorities in Greece have issued a public appeal to participate in vaccination and booster shot programs following a spike in measles cases in the country amid an outbreak in Europe.
The Greek Center for Disease Control and Prevention said Friday that 166 cases had been reported in the country in 2016-17, with an increase in recent days.
More than 17,000 measles cases have been reported in that period in 30 European countries monitored by the European Center for Disease Prevention and Control, resulting in 40 deaths.
The European agency said the highest concentration of cases was reported in Romania.
 

Vaccines and Global Health: The Week in Review 16 September 2017

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_16 September 2017

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Milestones :: Perspectives

Milestones :: Perspectives
 
The Mérieux Fondation is celebrating 50 years of fighting infectious diseases in developing countries
Les Pensiéres Center for Global Health, Veyrier-du-Lac (France)
September 14, 2017
Calling for all public and private stakeholders worldwide to rally together and international health diplomacy, it reasserts France’s central role.
To mark its 50th anniversary, the Foundation is organizing an International Meeting at the Les Pensières Center for Global Health on the shores of Lake Annecy. The aim of this day is to highlight new collaborative international approaches for fighting the increased risk of epidemics.

The threat of infectious disease is ever present, accounting for nearly 17 million victims each year, most of whom are children in developing countries. This threat is now taking on a new dimension in light of an increasing number of conflicts, demographic explosion, massive migrations of populations, accelerating global exchanges of all kinds and climate change – a context for which humans are largely responsible.

Traditional top-down approaches have demonstrated their limited efficacy in combating infectious diseases. They must now give way to new, local initiatives, conducted with and for the residents of those communities. Multidisciplinary approaches to global health go beyond merely treating patients, encompassing everything in the environment that impacts patients.

France has a role to play in this global fight, due to its expertise in infectious disease, Pasteurian tradition and the historical global influence of French medicine. As such, it needs to reassert its position and ensure it is an integral part of the wider framework of international health diplomacy, which is yet to be formed. The Foundation is ready to commit to this cause and provide its expertise in biology in the field.

To this end, over 150 scientists, researchers, doctors, biologists, humanitarian players and representatives from international organizations, hailing from West Africa, Asia, Latin America, Madagascar, Haiti and the Middle East are meeting together today to share their experiences at three round tables dedicated to key challenges:
:: Epidemic risks in developing countries, chaired by Professor Christian Bréchot, President of Institut Pasteur
:: New dynamics in health capacity building: leveraging local resources, chaired by Professor Ogobara Doumbo, Director of the Malaria Research and Training Centre, Faculty of Medicine, University of Bamako, Mali
:: The global health approach: bringing vulnerable populations more than medical care, chaired by Dr. Jean William Pape, Founder and Director of the GHESKIO Centers, Haiti

A single model for action to combat infectious diseases
For the past 50 years, the Mérieux Foundation has been committed to fighting infectious diseases affecting developing countries by strengthening their clinical biology capabilities.

Without diagnostics, medicine is blind. The Mérieux Foundation has therefore made its commitment to diagnostics the driving force behind its work. Diagnostics are an essential part of the healthcare chain and an invaluable tool for identifying pathogens responsible for disease and prescribing suitable treatment. They are therefore key to fighting bacterial resistance and, more globally, indispensable for disease surveillance and control.

The Foundation is focusing its actions on:
:: Creating and equipping laboratories of excellence, the Rodolphe Mérieux Laboratories;
:: Around these reference laboratories, renovating clinical laboratories in the field to give local populations access to quality diagnostics;
:: On-site training of new generations of healthcare players in these countries;
:: Rolling out international applied research programs, coordinated by its GABRIEL research network;
:: Building international research and diagnostic networks worldwide;
:: Developing global health programs to treat the most vulnerable, namely mothers and children.

Presided by Alain Mérieux, the Mérieux Foundation has public interest status and carries out its actions in concert with Fondation Christophe et Rodolphe Mérieux, an independent family foundation created in 2001 under the aegis of the Institut de France. Fondation Christophe et Rodolphe Mérieux is a 30% shareholder of the Institut Mérieux and is the sole beneficiary of the dividends paid out by the Institut.

The Mérieux Foundation employs over 100 people working in France and in developing countries and dedicates an annual budget of nearly €25 million to its actions in the field. Close to half this budget is provided by the family…
 
::::::
::::::
 
PATH announces new collaboration to advance maternal immunization in low- and middle-income countries
Announcement | September 11, 2017
The Advancing Maternal Immunization collaboration will create a roadmap to help infants survive and thrive by making immunization available to pregnant mothers
A newly launched collaboration is bringing together stakeholders from around the world to improve infant health and survival through maternal immunization, particularly in low- and middle-income countries (LMICs). The newly assembled Advancing Maternal Immunization (AMI) collaboration is meeting an urgent need for pregnant mothers in LMICs to be able to protect their babies from infectious diseases by getting vaccinated themselves—an option not used to its full potential in many parts of the world, especially in resource-limited settings where it is not widely available.
With a current focus on respiratory syncytial virus (RSV)—which is estimated to cause more than a quarter of global respiratory deaths (nearly 120,000) among children younger than five years of age annually—AMI aims to ensure that a successful RSV vaccine is made available to women in LMICs without delay. No licensed vaccine exists to prevent RSV, but a number of vaccine candidates are advancing, including a maternal vaccine in late-stage development that may be available in the next few years.
Coordinated by PATH in collaboration with the World Health Organization (WHO) and funded by the Bill & Melinda Gates Foundation, AMI will start by developing a roadmap to facilitate informed global, regional, and country decisions around RSV maternal vaccines. It will also identify requirements to enable rapid launch and uptake in LMICs…
 
::::::
::::::
 
New Gates Foundation Report Highlights Remarkable Progress Against Global Poverty and Disease, Warns Future Progress in Jeopardy
Bill and Melinda Gates Call for Strong Leadership to Address “Solvable Human Misery”
SEATTLE, Sept. 13, 2017 – The Bill & Melinda Gates Foundation today launched an inaugural annual report showcasing the remarkable progress that has been made in reducing extreme poverty and disease in recent decades, but issuing a stern warning to the world that future progress is in jeopardy.

Goalkeepers: The Stories Behind the Data, co-authored and edited by Bill and Melinda Gates and produced in partnership with the Institute for Health Metrics and Evaluation at the University of Washington, highlights past progress against some of the most devastating issues facing poor countries and uses breakthrough data projections to forecast good and bad future scenarios – with millions of lives hanging in the balance.

In all, the report tracks 18 data points from the UN Sustainable Development Goals, or Global Goals, including child and maternal deaths, stunting, access to contraceptives, HIV, malaria, extreme poverty, financial inclusion and sanitation. The report looks beneath the numbers to pinpoint the leaders, approaches and innovations that made a difference.

Through the data and first-person accounts from six contributors, the report showcases the stunning progress the world has made in the past generation: cutting extreme poverty and child deaths in half and reducing HIV deaths and maternal deaths by nearly half, among many other accomplishments. But as the report shows, serious challenges remain – including deep disparities between countries – and future progress is not inevitable.

The projections are showcased in charts and explore three potential 2030 scenarios for each indicator. The first is what could happen if we continue along the current path, based on past trends – without significant changes to approaches or current spending levels. Two additional scenarios provide a glimpse at a better and worse future: what could happen with strong leadership, innovation and investment and, starkly, what could happen if attention and funding waned. For example, a mere 10 percent cut in global donor funding for HIV treatment could result in more than 5 million more deaths by 2030…

Goalkeepers: The Stories Behind the Data 2017
Bill & Melinda Gates Foundation, 2017 :: 44 pages
PDF: http://www.globalgoals.org/goalkeepers/datareport/assets/downloads/Stories_behind_the_data_2017.pdf
[Excerpt p. 35]
VACCINES
Proportion of the target population covered by eight vaccines, conditional on inclusion in national vaccine schedules
Vaccines are one of the most impressive success stories in global health. More people are being immunized and protected against more diseases than ever before. The next steps for immunization programs are to battle stagnation by finding the pockets of inequity that exist within countries—even those with high average rates—and reach all children with a full set of lifesaving vaccinations. We’ve grouped countries and plotted the groups separately to show the gap between more and less developed countries.
Target: Support the research and development of vaccines and medicines for the communicable and noncommunicable diseases that primarily affect developing countries and provide access to affordable essential medicines and vaccines. Socio-demographic index (SDI) is a measure based on average income per capita, education attainment, and total fertility rate.
 
::::::
::::::
 
WHO – The 72nd Session of the United Nations General Assembly (UNGA 72)
12 – 25 September 2017
The 72nd Regular Session of the UN General Assembly (UNGA 72) will convene at UN Headquarters on Tuesday, 12 September 2017. The General Debate will open on Tuesday, 19 September 2017, with the theme, ‘Focusing on People: Striving for Peace and a Decent Life for All on a Sustainable Plan
The WHO Delegation to UNGA will be led by Dr Tedros, who will focus on raising awareness and building political commitment to his priority issues of universal health coverage; health security; women’s, children’s and adolescents’ health; and environmental health, including the health impacts of climate change. Dr Tedros, together with Deputy Head of Delegation Dr Flavia Bustreo and other senior officials, will organize and participate to many high-level events, including the flagship WHO event on Universal Health Coverage.
 [Details of major and side events at link above]

Emergencies

Emergencies
 POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 13 September 2017 [GPEI]
:: Following flooding in Benue, Nigeria, the World Health Organization has deployed its polio infrastructure across the state to strengthen disease prevention efforts.
:: Pakistan and Afghanistan plan to implement National Immunization Days during the second half of September.
:: Summary of newly-reported viruses this week: two new wild poliovirus type 1 (WPV1) positive environmental samples were confirmed this week, one located in Karachi, Pakistan, and the other in Rawalpindi, Pakistan
::::::
Situation reports on the polio outbreak in Syria [WHO]
Situation update 12 September 2017
:: No new cases of cVDPV2 were reported this week. The total number of cVDPV2 cases remains 39. All confirmed cases to date have had onset of paralysis before 14 July 2017.
:: Final lab results are pending for an additional 4 poliovirus type-2 (PV2) isolates (2 from Mayadeen and 1 from Boukamal districts, Deir Ez-Zor governorate, and 1 from Thawra district, Raqqa governorate).
:: The second round for Deir Ez-Zor concluded 28 August. Third party independent monitoring reported coverage of 77% (gauged by caregiver recall).
:: Preparations for the second Raqqa round continue.
:: The Ministry of Health has established healthy children stool sampling in all governorates receiving IDPs from Deir Ez-Zor and Raqqa.
:: IPV is being administered to unvaccinated children under five from Deir Ez-Zor and Raqqa at border checkpoints and entrances in all governorates.
:: The total number of AFP cases detected in Deir Ez-Zor governorate since the beginning of 2017 is 134 (99 from Mayadeen, 10 from Deir Ez-Zor, and 25 from Boukamal districts). Raqqa governorate has reported 16 AFP cases (5 from Raqqa, 10 from Tell Abyad, and 1 from Thawra districts). Homs governorate has reported 30 AFP cases (14 from Homs city, 13 from Rastan, 1 from Tadmour and 2 from Talkalakh districts).
::::::
::::::
WHO Grade 3 Emergencies  [to 16 September 2017]
Nigeria
:: WHO Intensifies Efforts to Contain Cholera Outbreak in Borno State
Maiduguri, 08 September 2017-With more than 1000 suspected and confirmed cases of cholera including 30 deaths in Borno state as of 07 Sept 2017, World Health Organization (WHO) has intensified its response efforts to contain the outbreak in Muna internally displaced persons (IDPs)camp in Maiduguri, Jere, Monguno and Dikwa local government areas (LGAs)…
 
The Syrian Arab Republic
:: Situation reports on the polio outbreak in Syria [WHO]  Situation update 12 September 2017
[See Polio above]
::::::
::::::
 
UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic
:: 15 Sep 2017  After three year siege, UNHCR aid convoy reaches Deir Ez-Zor in eastern Syria
Iraq
:: Iraq: Humanitarian Bulletin, September 2017 | Issued on 15 September
HIGHLIGHTS
…Humanitarian partners prepare for up to 85,000 displaced from Hawiga and surrounding areas.
…Iraq inter-agency toll-free call centre one of a kind in existence.
…Cash Working Group develops joint approach for assistance programmes.
…Iraq Humanitarian Fund prepares new allocation.
…Military operations in Hawiga may affect 85,000
Yemen  No new announcements identified.
::::::
UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Nigeria 
:: UN Aid Chief: Humanitarian response saves lives in Nigeria’s north-east, civilian safety must be prioritized
(Abuja, 12 September 2017): At the end of a two-day mission to Nigeria, the United Nations Under-Secretary-General for Humanitarian Affairs and Emergency Relief Coordinator, Mark Lowcock, said that the Government and humanitarians had made important progress in delivering life-saving relief to millions of people in north-east Nigeria. However, the complex Lake Chad Basin crisis will require sustained international support over the coming years…
:: Nigeria: Five ways to contain the cholera outbreak
:: Nigeria – North-East Flash Update No. 3 – Cholera Outbreak, 9 September 2017
Somalia 
:: Somalia: Drought Response – Situation Report No. 16  Published on 14 Sep 2017
[Highlights excerpts]
…There is progress on containment of the AWD/cholera outbreak with a significant decline in cases in August.
…Case numbers of measles remain high. A nationwide measles vaccination campaign is scheduled for November/December 2017.Health partners highlight the need for further funding for this campaign.
:: 7 Sep 2017  Somalia Civil-Military Working Group Report – August 2017
 
::::::
::::::
 
Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.
 
MERS-CoV [to 16 September 2017]
http://www.who.int/emergencies/mers-cov/en/
DONS
Middle East respiratory syndrome coronavirus (MERS-CoV) – Oman
12 September 2017
 
::::::
 
Cholera
Emergency cholera vaccination campaign kicks off in Sierra Leone
FREETOWN, 15 September 2017 – Sierra Leone’s first ever Oral Cholera Vaccination (OCV) campaign kicked off today, September 15th 2017. The emergency campaign targets communities affected by Western Area’s severe floods and landslides, which left over 6,000 people displaced and caused over 500 confirmed deaths.
“The cholera vaccine is safe and available free of cost for everyone living in the affected communities who is over 1 year of age,” said Dr. Brima Kargbo, Chief Medical Officer of the Ministry of Health and Sanitation. “We encourage people in these areas to take the two required doses of the vaccine, which will significantly increase protection against this life-threatening disease.”
Two doses of the vaccine are needed to maximize protection against cholera. The first dose will be administered from 15th to 20th September and the second from 5th to 10th October.  It will be available at health facilities and from health workers who will be going house-to-house in the affected communities and camps.
“Risks of cholera can increase after severe flooding and Sierra Leone has experienced severe outbreaks in the past,” said Alexander Chimbaru, Officer in-Charge of the World Health Organization in Sierra Leone. “In such situations, the cholera vaccine can be a valuable tool to reduce risks, alongside ongoing efforts to improve access to safe water, good hygiene practices and sanitation.”…

 WHO & Regional Offices [to 16 September 2017]

 WHO & Regional Offices [to 16 September 2017]

World hunger again on the rise, driven by conflict and climate change, new UN report says
   15 September 2017 – After steadily declining for over a decade, global hunger is on the rise again, affecting 815 million people in 2016, or 11 per cent of the global population, says a new edition of the annual United Nations report on world food security and nutrition released today.

Highlights
World Sepsis Day 2017
September 2017 – Sepsis is a life-threatening condition that arises when the body’s response to infection causes injury to its own tissues and organs. For World Sepsis Day 2017, WHO and partners are hosting a free online congress to shine a spotlight on neglected aspects of sepsis.

::::::

Weekly Epidemiological Record, 15 September 2017, vol. 92, 37 (pp. 537–556)
:: Meeting of the International Task Force for Disease Eradication, June 2017
 
::::::
 
WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Swaziland conducts Post MR and IPV vaccine Introduction Evaluation 15 September 2017
:: Emergency cholera vaccination campaign kicks off in Sierra Leone  15 September 2017
:: Cameroon investigates yaws outbreak among indigenous populations  15 September 2017
:: Uganda conducts preventative Polio immunization campaign  14 September 2017
:: WHO scales-up accountability processes as workshop on Key Performance Indicators integration opens in Abuja 14 September 2017
:: Mental health is a critical component in disaster response and recovery  13 September 2017
:: Nigeria collaborates with journalists on high quality measles vaccination campaign.
13 September 2017
:: Botswana embarks on a joint review of five health programmes! 13 September 2017
:: WHO supports Government of Uganda to develop a National Action Plan for Health Security (NAPHS)  12 September 2017
:: One year into emergency response, WHO evaluates operations in Northeastern Nigeria.
12 September 2017
:: Integrated Measles and EOS campaign protects 2.6 million children in Ethiopia’s Somali Region  11 September 2017

WHO Region of the Americas PAHO
:: Countries scale up mosquito control efforts for Mosquito Awareness Week (09/13/2017)
:: Wellness Week in the Americas promotes mental well-being (09/11/2017)

WHO South-East Asia Region SEARO
:: Bangladesh/Myanmar: Rakhine Conflict 2017   Situation Report: 01   Date: 15 September 2017
KEY HIGHLIGHTS  [excerpt]
:: Since 25 August more than 379,000 people are estimated to have crossed from Myanmar to Bangladesh following violence in Rakhine state, Myanmar
:: 156,000 are located in makeshift settlement/camps, 35 000 in host communities and 188 000 in new spontaneous settlements
:: 26,747 people have been displaced in Myanmar…
SITUATION OVERVIEW [excerpt]
:: WHO and UNICEF to support MOH on routine EPI and mass vaccination…
Public health concerns  [excerpt]
:: Routine vaccination rates are reported to be very low in northern Rakhine state (e.g. <70% coverage against measles 1 or 2), a reflection of a higher risk of outbreaks from expanded program on immunization-associated diseases…

WHO European Region EURO
:: Day 4 highlights: partnerships essential in our “multisectoral, multidimensional world” 14-09-2017
:: Day 3 highlights: “The health workforce is the beating heart of any health system” 13-09-2017
:: Day 2 highlights: Director-General outlines key health priorities 12-09-2017
:: Day 1 highlights: RC67 opens 11-09-2017
:: 67th session of WHO Regional Committee for Europe opens in Budapest 10-09-2017

WHO Eastern Mediterranean Region EMRO
:: WHO trains 2800 health care providers to respond to gender-based violence
13 September 2017 – WHO estimates that globally around 1 in 3 women have experienced either physical and/or sexual intimate partner violence or non-partner sexual violence. In Afghanistan, WHO, with the support of USAID and the Italian Development Cooperation, has trained over 2800 nurses, doctors and midwives on the gender-based violence protocol, which was developed by the Ministry of Public Health and WHO, with the support of UN Women in 2014. A further 6500 health care providers in all provinces are currently being trained on how to properly manage cases of gender-based violence, including physical, sexual and psychological violence…

CDC/ACIP [to 16 September 2017]

CDC/ACIP [to 16 September 2017]
http://www.cdc.gov/media/index.html

MMWR News Synopsis for September 14, 2017
:: Use of Unannounced Mystery Patient Drills to Assess Hospital Emergency Department Preparedness for Communicable Diseases of Public Health Concern — New York City, 2016
:: Rates and Trends of Pediatric Acute Lymphoblastic Leukemia — United States, 2001–2014
:: Occupational Animal Exposure Among Persons with Campylobacteriosis and Cryptosporidiosis Nebraska, 2005–2015
:: Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis

::::::

State Health Officials Strongly Encourage Influenza Vaccinations Among Pregnant Women
Association of State and Territorial Health Officials [U.S.]
ARLINGTON, Va., Sept. 14, 2017 /PRNewswire-USNewswire/ — Jay Butler, MD, ASTHO president and chief medical officer for the Alaska Department of Health and Social Services, released the following statement today regarding the importance of influenza vaccinations for pregnant women:
“As we enter flu season, state and territorial health officials strongly encourage all individuals six months or older to receive an annual influenza vaccination, including pregnant women and older adults. Each year, millions of Americans are affected by the flu and influenza vaccines are vital to reduce the chances of getting sick. Illness from influenza infection can be particularly dangerous for pregnant women and their developing babies.

A recent report from the ongoing Vaccine Safety Datalink project found that there may be a possible link between miscarriage early in pregnancy and the flu vaccine in women who received a certain version of the vaccine two years in a row. ASTHO and its members are concerned about this potential risk when weighed against other risks, including the risks posed by influenza during pregnancy, and continue to work with national healthcare organizations, including the American College of Obstetricians and Gynecologists and CDC, to determine whether these new findings should lead to any changes in national recommendations. Given the large volume of data indicating the safety of influenza vaccination during pregnancy, ASTHO and its members support current recommendations for use of vaccines during pregnancy.

This study raises an important question about risk, and an ongoing investigation to study this issue further is recommended. It is also important to note that this study does not prove that flu vaccine was the cause of the miscarriage. Earlier studies have not found a link between flu vaccination and miscarriage. CDC continues to recommend that pregnant women get an influenza vaccine during any trimester of their pregnancy because flu poses a danger to pregnant women, and a flu vaccine can prevent influenza in pregnant women which also protects their baby after birth.

State and territorial health departments continue to encourage pregnant women to get vaccinated to be protected from influenza during pregnancy. Immunizations are a vital public health tool and one of the most cost-effective means of public health promotion and disease prevention. Vaccines prevent disease, disability, and death in children and adults.”

Announcements  

Announcements
 
 BMGF – Gates Foundation  [to 16 September 2017]
http://www.gatesfoundation.org/Media-Center/Press-Releases
SEPTEMBER 13, 2017
New Gates Foundation Report Highlights Remarkable Progress Against Global Poverty and Disease, Warns Future Progress in Jeopardy
Bill and Melinda Gates Call for Strong Leadership to Address “Solvable Human Misery”
[See Week in Review above for more detail]
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 16 September 2017]
http://cepi.net/
[Undated]
Board member advert
CEPI is now looking for visionary leaders to serve on its new permanent Board and help guide the coalition through its next phase of growth, maximising the positive impact that CEPI can make in the years ahead.
To express your interest in being a member of CEPI’s board, or to nominate an individual you believe to be an exceptional candidate, please email board@cepi.net by October 1, 2017, providing a CV where possible.
PDF FORMAT – 50KB  Download

European Medicines Agency  [to 16 September 2017]
http://www.ema.europa.eu/ema/
15/09/2017
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11 to 14 September 2017
Thirteen medicines recommended for approval, including one orphan medicine

12/09/2017
Raising awareness of the perils of antimicrobial resistance
EMA to host a meeting with key stakeholders on the work of international health authorities and how to optimise collaboration …
 
FDA [to 16 September 2017]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
What’s New in Biologics
Influenza Virus Vaccine for the 2017-2018 Season
Updated: 9/14/2017
 
Fondation Merieux  [to 16 September 2017]
http://www.fondation-merieux.org/
September 14, 2017
The Mérieux Fondation is celebrating 50 years of fighting infectious diseases in developing countries
Les Pensiéres Center for Global Health, Veyrier-du-Lac (France)
[See Milestones above for more detail
 
Global Fund [to 16 September 2017]
http://www.theglobalfund.org/en/news/?topic=&type=NEWS;&country=
News
22 Million Lives Saved
13 September 2017
Programs supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria have saved 22 million lives, according to a report released today. The report also shows significant increases in the number of people receiving treatment for HIV, diagnosis and treatment for TB and having an insecticide treated net to prevent malaria…
The Global Fund Results Report 2017, with cumulative results through the end of 2016, shows a decline of one-third in the number of people dying from AIDS, TB and malaria in the countries where the Global Fund invests…
Programs supported by the Global Fund, which are designed and implemented by local experts and communities affected by the diseases, provided 11 million people with antiretroviral therapy for HIV – more than half the total number of people on treatment worldwide.
Global Fund-supported programs have provided 17.4 million people with testing and treatment for TB, and 795 million mosquito nets to prevent malaria. As a result of prevention and control interventions in more than 100 countries, the Global Fund’s target of averting 140-180 million infections by the end of 2016 was met in 2015…
Report pdf [52 pages]:
https://www.theglobalfund.org/media/6773/corporate_2017resultsreport_report_en.pdf
 
NIH  [to 16 September 2017]
http://www.nih.gov/news-events/news-releases
September 12, 2017
NIH awards $15 million to support development of 3-D human tissue models
“Tissue chips” to be engineered to model disease and test drug efficacy prior to clinical trials.

Dr. James Ostell named Director of the National Center for Biotechnology Information
September 11, 2017 — NCBI maintains biomedical databases, including PubMed, GenBank, BLAST, Entrez, RefSeq, dbSNP, PubMed Central and dbGaP.
 
PATH  [to 16 September 2017]
http://www.path.org/news/index.php
Announcement | September 14, 2017
PATH joins world leaders in New York City this week to advocate for innovation to create a healthier, more secure world

Announcement | September 11, 2017
PATH announces new collaboration to advance maternal immunization in low- and middle-income countries
[See Milestones above for more details]

UNAIDS [to 16 September 2017]
http://www.unaids.org/en
Update
Thailand launches new national strategy to end the AIDS epidemic by 2030
15 September 2017
The Ministry of Public Health of Thailand has launched its new 2017–2030 National AIDS Strategy, which provides a road map for ending the AIDS epidemic as a public health threat in Thailand by 2030. Narong Pipatanasai, Deputy Prime Minister and Chair of the National AIDS Committee, led the launch at the Government Complex in Bangkok, Thailand, on 13 September.
The 13-year plan adapts the latest global commitments to Thailand, ensuring an effective, cost-efficient and high-impact HIV response. A recent UNAIDS report on the global AIDS epidemic finds that annual new HIV infections dropped by 50% in Thailand between 2010 and 2016, the steepest decline for any country in the Asia and the Pacific region…

Update
UNAIDS and Malaysia launch joint data web platform
14 September 2017
UNAIDS and the Ministry of Health of Malaysia have launched a joint web platform that aims to strengthen the generation of strategic information and the use of national, subnational and key population data for evidence-informed programming.
The platform, which is hosted and supported by the UNAIDS regional data hub, was launched by Noor Hisham Abdullah, Director-General of Malaysia’s Ministry of Health, and Eamonn Murphy, Director of the UNAIDS Regional Support Team for Asia and the Pacific, at the 5th Asia Pacific Conference on Public Health, which ended on 13 September in Kuching, Malaysia…

Update
Metro Manila city leaders commit to intensifying HIV response
11 September 2017
Mayors and other city leaders from the 17 cities that make up the National Capital Region in the Philippines pledged to make the HIV epidemic a public health emergency requiring multisectoral strategies and a full provision of resources. The city representatives recently signed a city HIV resolution during a dinner meeting in Manila hosted by the Secretary of the Department of Health, Paulyn Jean Rosell-Ubial…
 
Wellcome Trust  [to 16 September 2017]
https://wellcome.ac.uk/news
News / Published: 12 September 2017
European foundations unite to tackle global challenges
Three of Europe’s biggest philanthropic foundations have joined together to award €5m to tackle some of the most pressing global challenges of our time.
Wellcome Trust, Volkswagen Stiftung and Riksbankens Jubileumsfond have funded six research groups as part of the Europe and Global Challenges Initiative. The projects range from understanding how to best protect and integrate Syrian refugees, to strengthening climate action in the global south. Each partner will fund two projects directly.
 
::::::
 
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 16 September 2017]
http://www.dcvmn.org/
25 September 2017 to 28 September 2017
DCVMN Annual General Meeting
Seoul / Korea
Download the Agenda
 
 
Industry Watch
:: FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over
LONDON, Sept. 13, 2017 /PRNewswire/ — GlaxoSmithKline plc announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted unanimously that the data support the efficacy and safety of Shingrix, for the prevention of herpes zoster (shingles) in adults ages 50 and over. FDA Advisory Committees provide non-binding recommendations for consideration by the FDA, with the final decision on approval made by the FDA.
Dr. Emmanuel Hanon, Senior Vice President and Head of Vaccines R&D for GSK said: “Shingles is a painful and potentially serious condition. The risk of developing shingles increases with age and it is estimated that up to one in three people in the United States will develop shingles. Today’s vote brings us one step closer to approval of Shingrix, which is specifically designed to overcome age-related weakening of the immune system.”
The Biologics License Application (BLA) was submitted to the FDA in October 2016…
 

Journal Watch

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

The relationship between burden of childhood disease and foreign aid for child health

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 16 September 2017)

Research article
The relationship between burden of childhood disease and foreign aid for child health
We sought to examine the relationship between child specific health aid (CHA) and burden of disease. Based on existing evidence, we hypothesized that foreign aid for child health would not be proportional to burden of disease….CHA has grown significantly over the last two decades. There is no clear relationship between CHA and burden of disease. This report provides a description of foreign aid for child health, and hopes to inform policy and decision-making regarding foreign aid.
Clay Bavinger, Paul Wise and Eran Bendavid

BMC Health Services Research 2017 17:655
Published on: 15 September 2017

A review of Grey and academic literature of evaluation guidance relevant to public health interventions

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 16 September 2017)

Research article
A review of Grey and academic literature of evaluation guidance relevant to public health interventions
Sarah Denford, Charles Abraham, Margaret Callaghan, Peter Aighton, Frank De Vocht and Steven Arris
S.Denford@Exeter.ac.uk
BMC Health Services Research 2017 17:643
Published on: 12 September 2017
Abstract
Background
Public Health evaluation is essential to understanding what does and does not work, and robust demonstration of effectiveness may be crucial to securing future funding. Despite this, programs are often implemented with poor, incomplete or no evaluation. Public health practitioners are frequently required to provide evidence for the effectiveness of their services; thus, there is a growing need for evaluation guidance on how to evaluate public health programs. The aim of this study is to identify accessible high-quality, evaluation guidance, available to researchers and practitioners and to catalogue, summarise and categorise the content of a subset of accessible, quality guides to evaluation.
Methods
We systematically reviewed grey and academic literature for documents providing support for evaluation of complex health interventions. Searches were conducted January to March 2015, and included academic databases, internet search engines, and consultations with academic and practicing public health experts. Data were extracted by two authors and sent to the authors of the guidance documents for comments.
Results
Our initial search identified 402 unique documents that were screened to identify those that were (1) developed by or for a national or international organization (2) freely available to all (3) published during or after 2000 (4) specific to public health. This yielded 98 documents from 43 organisations. Of these, 48 were reviewed in detail. This generated a detailed catalogue of quality evaluation guidance. The content included in documents covers 37 facets of evaluation.
Conclusions
A wide range of guidance on evaluation of public health initiatives is available. Time and knowledge constraints may mean that busy practitioners find it challenging to access the most, up-to-date, relevant and useful guidance. This review presents links to and reviews of 48 quality guides to evaluation as well as categorising their content. This facilitates quick and each access to multiple selected sources of specific guidance.

Lessons from a decade of individual-based models for infectious disease transmission: a systematic review (2006-2015)

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 16 September 2017)

Research Article
Lessons from a decade of individual-based models for infectious disease transmission: a systematic review (2006-2015)
Individual-based models (IBMs) are useful to simulate events subject to stochasticity and/or heterogeneity, and have become well established to model the potential (re)emergence of pathogens (e.g., pandemic influenza, bioterrorism). Individual heterogeneity at the host and pathogen level is increasingly documented to influence transmission of endemic diseases and it is well understood that the final stages of elimination strategies for vaccine-preventable childhood diseases (e.g., polio, measles) are subject to stochasticity. Even so it appears IBMs for both these phenomena are not well established. We review a decade of IBM publications aiming to obtain insights in their advantages, pitfalls and rationale for use and to make recommendations facilitating knowledge transfer within and across disciplines.
Lander Willem, Frederik Verelst, Joke Bilcke, Niel Hens and Philippe Beutels
BMC Infectious Diseases 2017 17:612
Published on: 11 September 2017

Informed consent and registry-based research – the case of the Danish circumcision registry

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 16 September 2017)

Debate
Informed consent and registry-based research – the case of the Danish circumcision registry
Research into personal health data holds great potential not only for improved treatment but also for economic growth. In these years many countries are developing policies aimed at facilitating such research often under the banner of ‘big data’. A central point of debate is whether the secondary use of health data requires informed consent if the data is anonymised. In 2013 the Danish Minister of Health established a new register collecting data about all ritual male childhood circumcisions in Denmark. The main purpose of the register was to enable future research into the consequences of ritual circumcision.
Thomas Ploug and Søren Holm
BMC Medical Ethics 2017 18:53
Published on: 15 September 2017

BMC Public Health (Accessed 16 September 2017)

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 16 September 2017)

Research article
A socio-ecological analysis of barriers to the adoption, sustainablity and consistent use of sanitation facilities in rural Ethiopia
Despite evidence showing that access to and use of improved sanitation is associated with healthier households and communities, barriers influencing the adoption and sustainablity of sanitation facilities rema…
Fikralem Alemu, Abera Kumie, Girmay Medhin, Teshome Gebre and Phoebe Godfrey
BMC Public Health 2017 17:706
Published on: 13 September 2017

Research article
Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b
Haemophilus influenzae serotype b (Hib) has yet to be eliminated despite the implementation of routine infant immunization programs. There is no consensus regarding the number of primary vaccine doses and an optimal schedule for the booster dose. We sought to evaluate the effect of a booster dose after receiving the primary series on the long-term disease incidence.
Nadia A. Charania and Seyed M. Moghadas
BMC Public Health 2017 17:705
Published on: 13 September 2017

Research article
Associations between media use and health information-seeking behavior on vaccinations in South Korea
Although vaccinations are critical for preventing emerging infectious diseases, scant research has been conducted on risk communication. With socio-economic characteristics, health behavior, and underlying diseases under control, we investigated associations between media use, health information-seeking behavior, health information type, and vaccination in the population.
Jiyeon Kim and Minsoo Jung
BMC Public Health 2017 17:700
Published on: 11 September 2017

Global Public Health Volume 12, 2017 Issue 11

Global Public Health
Volume 12, 2017   Issue 11
http://www.tandfonline.com/toc/rgph20/current

Article
Gender counts: A systematic review of evaluations of gender-integrated health interventions in low- and middle-income countries
Brittany Schriver, Mahua Mandal, Arundati Muralidharan, Anthony Nwosu, Radhika Dayal, Madhumita Das & Jessica Fehringer
Pages: 1335-1350
Published online: 07 Mar 2016

Article
A systematic review of microfinance and women’s health literature: Directions for future research
L. O’Malley & J. G. Burke

Pages: 1433-1460
Published online: 15 Apr 2016

Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 16 September 2017]

Research
Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
The recent introduction of Direct Acting Antivirals (DAAs) for treating Hepatitis C Virus (HCV) can significantly assist in the world reaching the international target of elimination by 2030. Yet, the challenge facing many individuals and countries today lies with their ability to access these treatments due to their relatively high prices. Gilead Sciences applies differential pricing and licensing strategies arguing that this provides fairer and more equitable access to these life-saving medicines. This paper analyses the implications of Gilead’s tiered pricing and voluntary licencing strategy for access to the DAAs.
Yibeltal Assefa, Peter S. Hill, Anar Ulikpan and Owain D. Williams
Globalization and Health 2017 13:73
Published on: 13 September 2017

Systems thinking in combating infectious diseases

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 16 September 2017]

Opinion
Systems thinking in combating infectious diseases
Shang Xia, Xiao-Nong Zhou and Jiming Liu
Published on: 11 September 2017
Abstract
The transmission of infectious diseases is a dynamic process determined by multiple factors originating from disease pathogens and/or parasites, vector species, and human populations. These factors interact with each other and demonstrate the intrinsic mechanisms of the disease transmission temporally, spatially, and socially. In this article, we provide a comprehensive perspective, named as systems thinking, for investigating disease dynamics and associated impact factors, by means of emphasizing the entirety of a system’s components and the complexity of their interrelated behaviors. We further develop the general steps for performing systems approach to tackling infectious diseases in the real-world settings, so as to expand our abilities to understand, predict, and mitigate infectious diseases.

Preventing Cancer and Other Diseases Caused by Human Papillomavirus Infection 2017 Lasker-DeBakey Clinical Research Award

JAMA
September 12, 2017, Vol 318, No. 10, Pages 883-974
http://jama.jamanetwork.com/issue.aspx

Viewpoint
Preventing Cancer and Other Diseases Caused by Human Papillomavirus Infection 2017 Lasker-DeBakey Clinical Research Award
Douglas R. Lowy, MD; John T. Schiller, PhD
JAMA. 2017;318(10):901-902. doi:10.1001/jama.2017.11706
In this Viewpoint, 2017 Lasker-DeBakey Clinical Medical Research Award winners Douglas Lowy and John Schiller discuss the development of the virus-like particle technology that was used to create the human papillomavirus vaccine to prevent cervical cancer and other diseases.

Navigating a new narrative for developing countries: rising strong

JBI Database of Systematic Review and Implementation Reports
September 2017 – Volume 15 – Issue 9
http://journals.lww.com/jbisrir/Pages/currenttoc.aspx

Editorials
Navigating a new narrative for developing countries: rising strong
Jordan, Zoe
JBI Database of Systematic Reviews and Implementation Reports . 15(9):2223-2224, September 2017.
[Excerpt]
…This issue of the JBI Database of Systematic Reviews and Implementation Reports includes    three editorials that highlight both the potential impact and real challenge that implementation of evidence in policy and practice can have in African settings. Okwen refers to the “complex symphony of an evidence ecosystem that requires innovative approaches from evidence generation to evidence implementation”.4(p.2227) This beautifully crafted sentiment is echoed by Bayuo in his editorial related to evidence utilization in Ghana as he describes the parallel “worlds” within which the desire and practice of evidence based healthcare live, given the significant contextual challenges faced by those working in the African context.5
These insightful editorials are accompanied by a range of pragmatic articles6-10 related to the synthesis and implementation of a range of evidence that once again highlight the unique needs and challenges of health professionals in Africa and other low income countries, and the inimitable contexts within which it needs to be considered and utilized.
Despite these challenges I believe that, internationally, we are rising strong. Increasingly we are finding new and creative ways to work collaboratively, cooperatively, collectively, and with common vision and commitment to drive the evidence based healthcare agenda forward in developing regions. I am confident that the narrative is indeed changing and changing for the better.

Journal of Community Health – Volume 42, Issue 5, October 2017

Journal of Community Health
Volume 42, Issue 5, October 2017
https://link.springer.com/journal/10900/42/5/page/1

Original Paper
State of HIV in the US Deep South
Susan Reif, Donna Safley, Carolyn McAllaster, Elena Wilson… Pages 844-853

Original Paper
Practices and Attitudes of Missouri School Nurses Regarding Immunization Records and Select Immunizations of Graduating High School Seniors
Darson L. Rhodes, Michele Draper, Kendra Woolman, Carol Cox Pages 872-87

Original Paper
Adolescent Participation in HPV Vaccine Clinical Trials: Are Parents Willing?
Jennifer Cunningham Erves, Tilicia L. Mayo-Gamble

Original Paper
Improving HPV Vaccination Through a Diverse Multi-state Coalition
Echo L. Warner, Brynn Fowler, Laura Martel, Deanna Kepka

Gray literature: An important resource in systematic reviews (pages 233–240)

Journal of Evidence-Based Medicine
August 2017  Volume 10, Issue 3  Pages 153–240
http://onlinelibrary.wiley.com/doi/10.1111/jebm.2017.10.issue-3/issuetoc

METHODOLOGY
Gray literature: An important resource in systematic reviews (pages 233–240)
Arsenio Paez
Version of Record online: 31 AUG 2017 | DOI: 10.1111/jebm.12266
Abstract
Systematic reviews aide the analysis and dissemination of evidence, using rigorous and transparent methods to generate empirically attained answers to focused research questions. Identifying all evidence relevant to the research questions is an essential component, and challenge, of systematic reviews. Gray literature, or evidence not published in commercial publications, can make important contributions to a systematic review. Gray literature can include academic papers, including theses and dissertations, research and committee reports, government reports, conference papers, and ongoing research, among others. It may provide data not found within commercially published literature, providing an important forum for disseminating studies with null or negative results that might not otherwise be disseminated. Gray literature may thusly reduce publication bias, increase reviews’ comprehensiveness and timeliness, and foster a balanced picture of available evidence.

Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study

Journal of Travel Medicine
Volume 24, Issue 5, 1 September 2017
https://academic.oup.com/jtm/issue/24/5

Original Article
Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study
This dose finding study demonstrates that priming with a single dose of rabies vaccine was sufficient to induce an adequate anamnestic antibody response to rabies PEP in all subjects 1 year later, even in those in whom the RVNA threshold of 0.5 IU/ml was not reached after priming.
Emile F.F. Jonker, MD; Leonardus G. Visser, MD, PhD
Journal of Travel Medicine, Volume 24, Issue 5, 1 September 2017, tax033,

The Lancet – Sep 16, 2017 Volume 390 Number 10100 p1083-1464

The Lancet
Sep 16, 2017 Volume 390 Number 10100 p1083-1464
http://www.thelancet.com/journals/lancet/issue/current

Global Health Metrics
Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016
GBD 2016 SDG Collaborators  –  Open Access

Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
GBD 2016 SDG Collaborators  –  Open Access

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
GBD 2016 SDG Collaborators  –  Open Access

Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
GBD 2016 SDG Collaborators  –  Open Access

Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
GBD 2016 SDG Collaborators  –  Open Access

Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016

The Lancet
Sep 16, 2017 Volume 390 Number 10100 p1083-1464
http://www.thelancet.com/journals/lancet/issue/current

Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016
GBD 2016 SDG Collaborators  –  Open Access
Summary
Background
The UN’s Sustainable Development Goals (SDGs) are grounded in the global ambition of “leaving no one behind”. Understanding today’s gains and gaps for the health-related SDGs is essential for decision makers as they aim to improve the health of populations. As part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016), we measured 37 of the 50 health-related SDG indicators over the period 1990–2016 for 188 countries, and then on the basis of these past trends, we projected indicators to 2030.
Methods
We used standardised GBD 2016 methods to measure 37 health-related indicators from 1990 to 2016, an increase of four indicators since GBD 2015. We substantially revised the universal health coverage (UHC) measure, which focuses on coverage of essential health services, to also represent personal health-care access and quality for several non-communicable diseases. We transformed each indicator on a scale of 0–100, with 0 as the 2·5th percentile estimated between 1990 and 2030, and 100 as the 97·5th percentile during that time. An index representing all 37 health-related SDG indicators was constructed by taking the geometric mean of scaled indicators by target. On the basis of past trends, we produced projections of indicator values, using a weighted average of the indicator and country-specific annualised rates of change from 1990 to 2016 with weights for each annual rate of change based on out-of-sample validity. 24 of the currently measured health-related SDG indicators have defined SDG targets, against which we assessed attainment.
Findings
Globally, the median health-related SDG index was 56·7 (IQR 31·9–66·8) in 2016 and country-level performance markedly varied, with Singapore (86·8, 95% uncertainty interval 84·6–88·9), Iceland (86·0, 84·1–87·6), and Sweden (85·6, 81·8–87·8) having the highest levels in 2016 and Afghanistan (10·9, 9·6–11·9), the Central African Republic (11·0, 8·8–13·8), and Somalia (11·3, 9·5–13·1) recording the lowest. Between 2000 and 2016, notable improvements in the UHC index were achieved by several countries, including Cambodia, Rwanda, Equatorial Guinea, Laos, Turkey, and China; however, a number of countries, such as Lesotho and the Central African Republic, but also high-income countries, such as the USA, showed minimal gains. Based on projections of past trends, the median number of SDG targets attained in 2030 was five (IQR 2–8) of the 24 defined targets currently measured. Globally, projected target attainment considerably varied by SDG indicator, ranging from more than 60% of countries projected to reach targets for under-5 mortality, neonatal mortality, maternal mortality ratio, and malaria, to less than 5% of countries projected to achieve targets linked to 11 indicator targets, including those for childhood overweight, tuberculosis, and road injury mortality. For several of the health-related SDGs, meeting defined targets hinges upon substantially faster progress than what most countries have achieved in the past.
Interpretation
GBD 2016 provides an updated and expanded evidence base on where the world currently stands in terms of the health-related SDGs. Our improved measure of UHC offers a basis to monitor the expansion of health services necessary to meet the SDGs. Based on past rates of progress, many places are facing challenges in meeting defined health-related SDG targets, particularly among countries that are the worst off. In view of the early stages of SDG implementation, however, opportunity remains to take actions to accelerate progress, as shown by the catalytic effects of adopting the Millennium Development Goals after 2000. With the SDGs’ broader, bolder development agenda, multisectoral commitments and investments are vital to make the health-related SDGs within reach of all populations.
Funding
Bill & Melinda Gates Foundation.

Measuring global health: motivation and evolution of the Global Burden of Disease Study

The Lancet
Sep 16, 2017 Volume 390 Number 10100 p1083-1464
http://www.thelancet.com/journals/lancet/issue/current

Viewpoint
Measuring global health: motivation and evolution of the Global Burden of Disease Study
Christopher J L Murray, Alan D Lopez
People everywhere, but particularly those charged with improving the health of populations, want to know whether human beings are living longer and getting healthier. There is an inherent fascination with quantification of levels and patterns of disease, the emergence of new threats to health, and the comparative importance of various risk factors for the health of populations. Before the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) was initiated, no comprehensive assessments of human health were done.

 

PLoS Neglected Tropical Diseases (Accessed 16 September 2017)

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 16 September 2017)
Viewpoints

Global health policy and neglected tropical diseases: Then, now, and in the years to come
Thomas Fürst, Paola Salari, Laura Monzón Llamas, Peter Steinmann, Christopher Fitzpatrick, Fabrizio Tediosi
Viewpoints | published 14 Sep 2017 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0005759

Research Article
Cost-effectiveness of a national enterovirus 71 vaccination program in China
Within the price range of current routine vaccines paid by the government, a national EV71 vaccination program would be cost-saving or highly cost-effective to prevent EV71 related morbidity, mortality, and use of health service among children younger than five years in China. Policy makers should consider including EV71 vaccination as part of China’s routine childhood immunization schedule.
Wenjun Wang, Jianwen Song, Jingjing Wang, Yaping Li, Huiling Deng, Mei Li, Ning Gao, Song Zhai, Shuangsuo Dang, Xin Zhang, Xiaoli Jia
| published 11 Sep 2017 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0005899

Rapid qualitative research methods during complex health emergencies: A systematic review of the literature

Social Science & Medicine
Volume 189, Pages 1-170 (September 2017)
http://www.sciencedirect.com/science/journal/02779536/189?sdc=1
Review article
Rapid qualitative research methods during complex health emergencies: A systematic review of the literature
Review Article
Pages 63-75
Ginger A. Johnson, Cecilia Vindrola-Padros
Abstract
The 2013–2016 Ebola outbreak in West Africa highlighted both the successes and limitations of social science contributions to emergency response operations. An important limitation was the rapid and effective communication of study findings. A systematic review was carried out to explore how rapid qualitative methods have been used during global heath emergencies to understand which methods are commonly used, how they are applied, and the difficulties faced by social science researchers in the field. We also asses their value and benefit for health emergencies. The review findings are used to propose recommendations for qualitative research in this context. Peer-reviewed articles and grey literature were identified through six online databases. An initial search was carried out in July 2016 and updated in February 2017. The PRISMA checklist was used to guide the reporting of methods and findings. The articles were assessed for quality using the MMAT and AACODS checklist. From an initial search yielding 1444 articles, 22 articles met the criteria for inclusion. Thirteen of the articles were qualitative studies and nine used a mixed-methods design. The purpose of the rapid studies included: the identification of causes of the outbreak, and assessment of infrastructure, control strategies, health needs and health facility use. The studies varied in duration (from 4 days to 1 month). The main limitations identified by the authors were: the low quality of the collected data, small sample sizes, and little time for cross-checking facts with other data sources to reduce bias. Rapid qualitative methods were seen as beneficial in highlighting context-specific issues that need to be addressed locally, population-level behaviors influencing health service use, and organizational challenges in response planning and implementation. Recommendations for carrying out rapid qualitative research in this context included the early designation of community leaders as a point of contact, early and continuous sharing of findings, and development of recommendations with local policy makers and practitioners.

Communicable and non-communicable disease risks at the Grand Magal of Touba: The largest mass gathering in Senegal

Travel Medicine and Infectious Diseases
July-August, 2017 Volume 18
http://www.travelmedicinejournal.com/

Articles in Press
Communicable and non-communicable disease risks at the Grand Magal of Touba: The largest mass gathering in Senegal
Cheikh Sokhna, Balla Mbacké Mboup, Papa Gallo Sow, Gaoussou Camara, Mamadou Dieng, Mbaké Sylla, Lamine Gueye, Doudou Sow, Aldiouma Diallo, Philippe Parola, Didier Raoult, Philippe Gautret
Publication stage: In Press Corrected Proo
Preview
An estimated 4–5 million individuals gather each year in the holy city of Touba, Senegal during the Grand Magal religious pilgrimage. Pilgrims come from across Senegal and the surrounding countries, as well as from countries outside Africa. It is the largest mass gathering (MG) of the Mouride community and the largest Muslim religious MG in West Africa.

Pneumococcal vaccination: Direct and herd effect on carriage of vaccine types and antibiotic resistance in Icelandic children

Vaccine
Volume 35, Issue 39, Pages 5225-5308 (18 September 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/38?sdc=1

Original Research Article
Pneumococcal vaccination: Direct and herd effect on carriage of vaccine types and antibiotic resistance in Icelandic children
Pages 5242-5248
Samuel Sigurdsson et al…
Abstract
Background
Since the introduction of pneumococcal conjugate vaccines, vaccine type pneumococcal carriage and disease has decreased world-wide. The aim was to monitor changes in the nasopharyngeal carriage of pneumococci, the distribution of serotypes and antimicrobial resistance in children before and after initiation of the 10-valent pneumococcal vaccination in 2011, in a previously unvaccinated population.
Methods
Repeated cross-sectional study at 15 day-care centres in greater Reykjavik area. Nasopharyngeal swabs were collected yearly in March from 2009 to 2015. The swabs were selectively cultured for pneumococci, which were serotyped using latex agglutination and/or PCR and antimicrobial susceptibility determined. Two independent studies were conducted.
In study 1, on total impact, isolates from children aged <4 years were included. The vaccine-eligible-cohort (birth-years: 2011–2013, sampled in 2013–2015) was compared with children at the same age born in 2005–2010 and sampled in 2009–2012. In study 2 on herd effect, isolates from older non-vaccine-eligible children (3.5–6.3 years) were compared for the periods before and after the vaccination (2009–2011 vs 2013–2015. Vaccine impact was determined using 1-odds-ratio.
Results
Following vaccination, the vaccine impact on vaccine type acquisition was 94% (95% CI: 91–96%) in study 1 and 56% (95% CI: 44–65%) in study 2. The impact on serotype 6 A was 33% (95% CI: −9%; 59%) in study 1 and 42% (95% CI: 10–63%) in study 2 with minimal effect on 19A. The non-vaccine serotypes/groups 6C, 11, 15 and 23B were the most common serotypes/groups after vaccination. Isolates from the vaccine-eligible-cohort had lower penicillin MICs, less resistance to erythromycin and co-trimoxazole and less multi resistance than isolates from the control-group.
Conclusions
The efficacy of the vaccination on vaccine serotypes was high, and a milder effect on vaccine-associated-serotype 6A was observed for the vaccine-eligible-cohort. There was a significant herd effect on vaccine types in older non-vaccine-eligible children. Overall antimicrobial non-susceptibility was reduced.

Vaccination coverage among social and healthcare workers in ten countries of Samu-social international sites

Vaccine
Volume 35, Issue 39, Pages 5225-5308 (18 September 2017)
http://www.sciencedirect.com/science/journal/0264410X/35/38?sdc=1

Vaccination coverage among social and healthcare workers in ten countries of Samu-social international sites
Original Research Article
Pages 5291-5296
Esaie Marshall, Dominique Salmon, Nadia Bousfiha, Yacouba Togola, François Ouedraogo, Maud Santantonio, Coumba Khadidja Dieng, Suzanne Tartière, Xavier Emmanuelli
Abstract
Background
We aim to determine the vaccination coverage of social and healthcare workers in International sites of Samusocial, providing emergency care to homeless people, and to assess factors associated with having received necessary doses at adulthood.
Methods
Data on immunization coverage of social and healthcare workers were provided by a cross-sectional survey, conducted from February to April 2015 among 252 Samusocial workers in 10 countries. Vaccination status and characteristics of participants were collected through a self-administered questionnaire. Prevalence rate ratio (PRR) of vaccination status was calculated using Poisson regression models.
Results
Among 252 Samusocial social and health workers who felt a questionnaire, median age was 39 years, 42.1% were female, 88.9% were in contact with homeless beneficiaries (19.1% health workers). Overall, 90.1% of Samusocial staff felt adult vaccinations was useful and 70.2% wished to receive booster doses in future. Vaccination coverage at adulthood was satisfactory for diphtheria and poliomyelitis (96%), but low for influenza (20.8%), meningococcus (50.5%), hepatitis B (56.3%), yellow fever (58.1%), measles (81.3%) and pertussis (90.7%). The main reasons for not having received vaccination booster doses were forgetting the dates of booster doses (38.4%) and not having received the information (13.5%). In adjusted analysis, prevalence of up-to-date for vaccination schedule was 35% higher among health workers than among social workers (aPRR=1.35, 95%CI: 1.01–1.82, P=0.05) and was 56% higher among workers who had a documentary evidence of vaccination than in those who did not (aPRR=1.56, 95%CI: 1.19–2.02, P=0.001).
Conclusions
The Samusocial International workers vaccine coverage at adulthood was insufficient and disparate by region. It is necessary to strengthen the outreach of this staff and increase immunization policy for hepatitis B, diphtheria, tetanus, and measles, as well as for yellow fever, rabies and meningococcal ACYW135 vaccines in at risk regions.
 
 
 

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary
 
 
Vaccine
Available online 7 September 2017
Review
Considerations for use of Ebola vaccine during an emergency response
JA Walldorf, EA Cloessner, TB Hyde, A MacNeil…
Abstract
Vaccination against Ebola virus disease is a tool that may limit disease transmission and deaths in future outbreaks, integrated within traditional Ebola outbreak prevention and control measures. Although a licensed Ebolavirus vaccine (EV) is not yet available, the 2014–2016 West African Ebola outbreak has accelerated EV clinical trials and given public health authorities in Guinea, Liberia, and Sierra Leone experience with implementation of emergency ring vaccination. As evidence supporting the use of EV during an outbreak response has become available, public health authorities in at-risk countries are considering how to integrate EV into future emergency Ebola responses and for prevention in high-risk groups, such as healthcare workers and frontline workers (HCW/FLWs), even before an EV is licensed. This review provides an overview of Ebola epidemiology, immunology, and evidence to inform regional and country-level decisions regarding EV delivery during an emergency response and to at-risk populations before a licensed vaccine is available and beyond. Countries or regions planning to use EV will need to assess factors such as the likelihood of a future Ebolavirus outbreak, the most likely species to cause an outbreak, the availability of a safe and effective EV (unlicensed or licensed) for the affected population, capacity to implement Ebola vaccination in conjunction with standard Ebola outbreak control measures, and availability of minimum essential resources and regulatory requirements to implement emergency Ebola vaccination. Potential emergency vaccination strategies for consideration include ring or geographically targeted community vaccination, HCW/FLW vaccination, and mass vaccination. The development of guidelines and protocols for Ebola vaccination will help ensure that activities are standardized, evidence-based, and well-coordinated with overall Ebola outbreak response efforts in the future.
 
 
Gut Microbes
Accepted author version posted online: 11 Sep 2017
Brief Report
Rotavirus Vaccine Response Correlates with the Infant Gut Microbiota Composition in Pakistan
V Harris, A Ali, S Fuentes, K Korpela, M Kazi, J Tate…
Abstract
Background
Rotavirus (RV) is the leading cause of diarrhea-related death in children worldwide, and ninety-five percent of rotavirus deaths occur in Africa and Asia. Rotavirus vaccines (RVV) can dramatically reduce RV deaths, but have low efficacy in low-income settings where they are most needed. The intestinal microbiome may contribute to this decreased RVV efficacy. This pilot study hypothesizes that infants’ intestinal microbiota composition correlates with RVV immune responses and that RVV responders have different gut microbiota as compared to non-responders.
Methods
We conducted a nested, matched case-control study comparing the pre-vaccination intestinal microbiota composition between 10 6-week old Pakistani RVV-responders, 10 6-week old Pakistani RVV non-responders, and 10 healthy Dutch infants.  RVV response was defined as an Immunoglobulin A of ≥20 IU/mL following Rotarix™(RV1) vaccination in an infant with a pre-vaccination IgA<20. Infants were matched in a 1:1 ratio using ranked variables: RV1 dosing schedule (6/10/14; 6/10; or 10/14 weeks), RV season, delivery mode, delivery place, breastfeeding practices, age and gender. Fecal microbiota analysis was performed using a highly reproducible phylogenetic microarray.
Results
RV1 response correlated with a higher relative abundance of bacteria belonging to Clostridium cluster XI and Proteobacteria, including bacteria related to Serratia and Escherichia coli. Remarkably, abundance of these Proteobacteria was also significantly higher in Dutch infants when compared to RV1-non-responders in Pakistan.
Conclusions
This small but carefully matched study showed the intestinal microbiota composition to correlate with RV1 seroconversion in Pakistan infants, identifying signatures shared with healthy Dutch infants.
Clinicaltrials.gov: NCT02220439

Health Behavior and Policy Review
2017  Volume 4, Number 5
Do Political and Religious Affiliations Impact HPV Vaccine Mandate Support?
BL Rosen, EL Thompson, KL Wilson, ML Smith –
Abstract
Objective: We attempted to identify characteristics of female college students supporting HPV vaccination mandates for school-aged youth and compare HPV vaccination mandate support by religious and political affiliations.
Methods: We analyzed data from 1034 college students. A multinomial logistic regression model was fitted using backwards stepwise entry.
Results: Students who self-identified as atheist and reported their parents supported HPV vaccination mandates were more likely to support HPV vaccination mandates. Those who believed mandates violated personal individual freedoms and parental rights were less likely to support mandates.
Conclusions: Interventions could focus on providing more education to groups more likely to oppose a mandate, thereby increasing support to protect school-aged youth from HPV.

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.
 
The Atlantic
http://www.theatlantic.com/magazine/
Accessed 16 September 2017
Bill Gates and Melinda Gates on Foreign Aid – The Atlantic
A new report from the Gates Foundation shows the devastating effects of a lapse in funding for global health.
Olga Khazan  Sep 13, 2017
 
Forbes
http://www.forbes.com/
Accessed 16 September 2017
Millions Could Die If Foreign Aid Is Cut, Gates Foundation Warns
13 September 2017

Dogs’ Immune Systems Are Much Like Ours And That’s A Boon To Cancer Research
Arlene Weintraub, Contributor
13 September 2017
The recent success of immune-boosting cancer treatments like checkpoint inhibitors and CAR-T cells has intensified the demand for more immunotherapy innovations. Pet dogs could help in the effort.

New York Times
http://www.nytimes.com/
Accessed 16 September 2017
Outbreak of Disease Carried by Mosquitoes Halts Blood Donation in Rome
Italian health officials have banned residents across half of Rome from donating blood because of an outbreak of the painful, mosquito-borne illness Chikungunya.
September 14, 2017 – By REUTERS ”

Study Prompts Call to Examine Flu Vaccine and Miscarriage
A puzzling study of U.S. pregnancies found that women who had miscarriages between 2010 and 2012 were more likely to have had back-to-back annual flu shots that included protection against swine flu.
September 13, 2017 – By THE ASSOCIATED PRESS

Wall Street Journal
http://online.wsj.com/home-page?_wsjregion=na,us&_homepage=/home/us
Accessed 16 September 2017
Your Health
Less Than Half of U.S. Teens Complete HPV Vaccinations
By Sumathi Reddy
Sep. 11, 2017 10:56 am ET
New research finds 43% get the full set of shots, while over 80% get Tdap and meningitis vaccines at the same age.

Washington Post
http://www.washingtonpost.com/
Accessed 16 September 2017
Study prompts call to examine flu vaccine and miscarriage
Mike Stobbe | AP · National · Sep 13, 2017

Think Tanks et al

Think Tanks et al
 
Brookings
http://www.brookings.edu/
Accessed 16 September 2017
Report
Private Sector Investment in Global Health R&D
Spending Levels, Barriers, and Opportunities
Darrell M. West, John Villasenor, and Jake Schneider
In this report—the second published by the Project—authors Darrell West, John Villasenor, and Jake Schneider examine current private sector spending by pharmaceutical firms, venture capital funds, and impact investors in global health R&D. They analyze three types of R&D spending and, using data from a number of sources, calculate how much the private sector currently invests in each:
::Overall R&D focused on drugs, vaccines, and therapeutics in the developed and developing world: The authors calculate that there is an annual total of at least $159.9 billion spent on overall health R&D. This includes $156.7 billion from pharmaceutical companies and at least $3.2 billion from venture capital.
:: Global health R&D that emphasizes medical treatments in the developing world: An estimated annual total of $5.9 billion is spent on global health R&D focused on the developing world, with $5.6 billion coming from pharmaceutical firms and $225.8 million from venture capital companies.
:: Neglected disease R&D, which focuses on drugs, vaccines, and therapeutics for 35 specific illnesses that primarily impact populations in very poor nations: This category attracts the least private R&D money with a total of $471 million from pharmaceutical funders and $40 million from impact investors. (see full report)

Vaccines and Global Health: The Week in Review 9 September 2017

Vaccines and Global Health: The Week in Review is a weekly digest  summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_9 September 2017

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

Milestones :: Perspectives

Milestones :: Perspectives
 
 
PATH boosts leadership in developing and introducing urgently needed vaccines
PATH’s Center for Vaccine Innovation and Access attracts top global talent and additional $120 million investment from the Bill & Melinda Gates Foundation
Seattle, September 6, 2017—Building on decades of innovation in vaccine development and immunization, PATH announced today it has received a $120 million grant from the Bill & Melinda Gates Foundation to further strengthen its PATH Center for Vaccine Innovation and Access (CVIA), which works across every stage of vaccine research, development, and introduction for diseases in low-resource settings.

PATH also announced that several global experts in vaccine development and introduction have joined PATH CVIA to advance these critical vaccine efforts.

“We are excited to continue our long-standing partnership with the Bill & Melinda Gates Foundation to develop and introduce vaccines for the families and communities that need them most,” commented Steve Davis, president and CEO of PATH. “We are working on vaccines against over a dozen deadly diseases and partnering with governments and companies around the world to save lives and improve health through vaccine innovation and immunization.”

CVIA operates across the entire vaccine development and delivery spectrum—from preclinical research on novel candidates through pivotal clinical evaluations and, ultimately, innovative approaches for new vaccine introduction.

“From specific vaccine successes against Meningitis A and Japanese encephalitis to game-changing immunization supply chain technologies like the vaccine vial monitor, PATH has an impressive track record in saving lives through vaccine innovations,” commented Trevor Mundel, president of Global Health for the Bill & Melinda Gates Foundation. “We are delighted to support CVIA, a center of excellence for vaccine development and introduction.”…

PATH welcomed new experts in vaccine development and introduction who have joined the CVIA leadership team:
:: Fred Cassels, global head, Enteric and Diarrheal Diseases, served as chief of the Enteric and Hepatic Diseases Branch at the National Institutes of Health.
:: Bruce Innis, global head, Respiratory Infections and Maternal Immunization, brings his experience with GlaxoSmithKline, most recently as vice president and senior vaccine development leader for Influenza and Dengue Vaccines, and previous experience with the US Army as chief of the Department of Virus Diseases at the Walter Reed Army Institute of Research.
:: Harshvardhan (Hersh) Mehta, global head, Development (Chemistry, Manufacturing, and Controls), has over two decades of experience in senior roles for Merck, Sanofi, MedImmune, and Roche.
:: Karen Midthun, global head, Regulatory, served as director of the US Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and Research between 2009 and 2016 and served during the prior 16 years in progressively senior roles within FDA.

“It is an honor to welcome these world-renowned vaccine authorities to PATH,” commented David C. Kaslow, PATH vice president for Essential Medicines and global head of CVIA. “Together with PATH’s existing expertise, these new leaders will help PATH and our partners bring lifesaving and affordable vaccines to people living in the poorest communities around the world.”

PATH veterans taking on new roles to round out the CVIA leadership team include:
:: Deborah Atherly, global head, Policy, Access, & Introduction.
:: Ashley Birkett, global head, Malaria Vaccines.
:: Jorge Flores, global head, Clinical.
:: John Konz, global head, Integrated Portfolio & Financial Management.
:: Jessica Milman, managing director, CVIA.
:: Katya Spielberg, global head, Finance & Contract Management.

“We’re proud of our two decades of developing and delivering vaccines that are saving millions of lives,” added Steve Davis, president and CEO of PATH. “With this solid base of funding and this world-class team, PATH can do even more to combat age-old scourges and emerging threats.”

::::::
::::::
 
NCI’s Douglas R. Lowy and John T. Schiller to receive 2017 Lasker Award
Wednesday, September 6, 2017
Two scientists at the National Cancer Institute (NCI) will receive the 2017 Lasker-DeBakey Clinical Medical Research Award for their significant research leading to the development of human papillomavirus (HPV) vaccines. The award is the country’s most prestigious biomedical research prize, and will be presented to John T. Schiller, Ph.D., of NCI’s Center for Cancer Research (CCR), and Douglas R. Lowy, M.D., also in CCR and acting director of NCI. NCI is part of the National Institutes of Health.

Dr. Lowy’s and Dr. Schiller’s collaborative work to understand and prevent HPV infection has led to the approval of three preventive HPV vaccines by the U.S. Food and Drug Administration.

“I’m incredibly proud of this much-deserved honor bestowed upon John and Doug for their foundational discoveries that led to the creation of HPV vaccines,” said NIH Director Francis S. Collins, M.D., Ph.D. “Thanks to their extraordinary efforts, we have the potential to eliminate cervical cancer and greatly reduce other HPV-associated cancers. This award reinforces the critical importance of basic research in the development of medical breakthroughs like the HPV vaccine.”

Efforts to develop these vaccines were spurred by an urgent public health need. Infection with certain types of HPV causes almost all cases of cervical cancer, the fourth most common cancer in women worldwide. More than 500,000 women around the world are diagnosed with cervical cancer each year, many of them at relatively young ages. More than 275,000 women die from the disease annually, and most of these deaths occur in developing regions of the world. Without successful interventions, the worldwide incidence and mortality from cervical cancer is projected to increase indefinitely. HPV infection also causes anal, vulvar, vaginal, penile, and oropharyngeal cancers.

While working to address the need to prevent HPV-caused cancers in the 1990s, a team led by Drs. Schiller and Lowy discovered that the proteins that form the outer shell of HPV could form virus-like particles (VLPs) that closely resemble the original virus but are not infectious. They found that these VLPs could trigger the immune system to produce high levels of protective antibodies that can neutralize the virus in a subsequent infection. The VLPs ultimately became the basis of the three current HPV vaccines: Gardasil, Gardasil 9, and Cervarix.

Drs. Lowy and Schiller say this breakthrough was possible because of earlier discoveries, and that it demonstrates the importance of long-term, publicly supported basic research.

“People have known since the 19th century that cervical cancer behaved as a sexually transmitted disease, but it wasn’t until the discoveries of Harald zur Hausen and his colleagues that HPV was found to be the cause. Development of the vaccines built upon decades of publicly supported research,” said Dr. Lowy. “We’re honored to be included with the other luminaries who have received this prestigious award.”

It is estimated that widespread uptake of current HPV vaccines could reduce the incidence and mortality of cervical cancer by more than two-thirds. Researchers are currently working to find ways to encourage uptake of the vaccines by lowering costs and simplifying the logistics of vaccination, especially in the developing world where most cervical cancers occur.

“This year’s Lasker Medical Research Awards illustrate the power of biomedical investigation to advance human health, whether scientists probe basic questions that reveal unforeseen truths or pursue goal-directed projects,” said Joseph L. Goldstein, M.D., chairman of the Department of Molecular Genetics at University of Texas Southwestern Medical Center, and chair of the Lasker Medical Research Awards Jury. “Douglas Lowy and John Schiller discovered that a single protein from the capsule of papillomaviruses can self-assemble into virus-like particles, paving the way for HPV vaccines that prevent cervical and other cancers.” …
 

Emergencies

Emergencies
 
POLIO
Public Health Emergency of International Concern (PHEIC)
Polio this week as of 6 September 2017 [GPEI]
:: Summary of newly-reported viruses this week: Pakistan: one new wild poliovirus type 1 (WPV1) case from Karachi (pre-notified last week) and four environmental WPV1-positive samples.

::::::
::::::

WHO Grade 3 Emergencies  [to 9 September 2017]
Yemen
Weekly epidemiology bulletin, 28 August–3 September 2017
Highlights
Country and Governorate level (cumulative)
– The cumulative total from 27 April 2017 to 3 September 2017 is 612,009 suspected cases and 2,047 associated deaths (CFR 0.33). 25,883 suspected cases and 11 associated deaths were reported in W35.
– The national attack rate is 215 per 10,000. The five governorates with the highest cumulative attack rates per 10,000 remain Amran (540), Al Mahwit (504), Al Dhale’e (482), Abyan (388) and Hajjah (288).
– Children under 5 years old represent 24% of total suspected cases.
– In total, 11,414 rapid diagnostic tests (RDT) have been performed which represents 18.7% coverage. The coverage for culture is 16.9%.
Conclusions and actions taken
– WHO is on full alert and is following the evolution of the outbreak each day in close collaboration with local health authorities.
– Initial investigations began on 31 August. A key objective is to determine whether the numbers are accurate and whether the increase in suspected cases is, in fact, caused by cholera, another diarrhoeal disease, or another reason.
– Three teams of international medical experts and epidemiologists are conducting investigations in Aden, Al-Hudaydah and Ibb governorates.
– These teams are traveling out to the worst-affected districts in these three governorates, visiting local health authorities and health facilities to determine the reason for this sudden escalation in suspected cases.

::::::
 
UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic
:: 8 Sep 2017  Children caught up in the aftermath of violence in Syria and Iraq need immediate protection and assistance

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Nigeria 
:: Nigeria – North-East Flash Update No. 2 – Cholera Outbreak, 6 September 2017

Ethiopia
:: Key Messages: Ethiopia humanitarian context , 8 September 2017
Third consecutive poor/failed rains exacerbate drought conditions in Ethiopia: Southern and eastern Ethiopia continue to battle the impact of drought caused by the Indian Ocean-related weather systems in 2016, exacerbated by below average spring rains this year – the third consecutive poor/failed rains in the southern and eastern regions. The drought conditions are compounded by disease outbreaks, large scale loss of livelihood assets and displacement.

The number of people requiring food assistance has increased by 3 million: At least 8.5 million people require relief food assistance in the second half of 2017, up from 5.6 million at the beginning of the year. In addition, 3.6 million moderately malnourished children and pregnant and lactating mothers will require supplementary feeding, at least 376,000 children are expected to become severely acutely malnourished and some 10.5 million people will not have regular access to safe drinking water until the end of 2017. Separately, some 4 million Public Works clients of the Productive Safety Net Program (PSNP) will require sustained assistance to the end of 2017. Although not formally included in the Mid-Year Review of Ethiopia’s 2017 Appeal, the financial requirements are estimated at US$300 million.

International partners scaling-up operations in support of the Government-led response: The UN and NGO partners have scaled-up response and further strengthened leadership and coordination functions in support of the Government-led response. With available, albeit quickly depleting resources, operational partners are pushing forward with the integrated, adaptable and scaled-up response in response to the rapidly changing humanitarian context and priorities.

Growing needs are outpacing the level of funding: with Government and donor contributions and commitments in 2016 and 2017, the initial projected requirement for Ethiopia’s humanitarian response was well funded. But an increase in those needing assistance following the Mid-Year Review means that there will at least be an outstanding gap of US$417.6 million for the rest of the year. Additional funding is urgently needed, especially at this critical juncture where any further delay in food assistance will have a domino effect on levels of malnutrition, and associated health complications particularly amongst children and the internally displaced.

The impact of back to back droughts underscores the need to prioritize development programming: The Government and its international partners are also investing in long-term development cooperation programs to reduce vulnerability to drought, including through accelerated urban development and industrial transformation. Ethiopia’s investments in basic services, including health, education and agriculture extension services, have helped make the poorest and most food insecure more resilient but much remains to be done. Increased joint planning between humanitarian and development systems is essential. Studies have shown that every dollar spent on resilience programming saves three dollars in humanitarian assistance.

:: 4 Sep 2017  Ethiopia Humanitarian Bulletin Issue 35 | 21 August – 3 September 2017

::::::
::::::

Cholera
[See WHO Grade 3 Emergencies – Yemen above]
 
WHO issues updated cholera vaccines position paper
29 August 2017
In an updated position paper on cholera vaccines published in the August edition of the Weekly Epidemiological Record, WHO incorporates recent developments in the field of cholera and provides revised guidance on the target populations for immunization.
::::::
 
Joint Press Release – Sierra Leone Ministry of Health and Sanitation, WHO, UNICEF, Gavi
Sierra Leone to begin cholera vaccination drive in disaster-affected areas
More than 1 million doses of Gavi-funded cholera vaccines heading to Sierra Leone after severe flooding and landslides
FREETOWN, 5 September 2017 – Half a million people in Sierra Leone will be able to access the life-saving cholera vaccine within weeks, the country’s Ministry of Health and Sanitation announced.

The vaccines will be received from the Gavi-funded global stockpile and will target areas particularly affected by August’s floods and deadly landslide, which resulted in over 500 confirmed deaths. Hundreds more people were reported missing in the wake of the disaster, according to the Office of National Security, while thousands were displaced from their homes.
“Cholera is a devastating disease which spreads quickly and kills fast, and risks can increase after severe flooding,” said Dr. Brima Kargbo, Chief Medical Officer at the Ministry of Health and Sanitation. “The oral cholera vaccine is an important tool to better protect the country and affected communities against the disease, which will ultimately save lives.”

Two rounds of vaccination are planned to run from September and will be delivered in 25 affected communities by the Government of Sierra Leone with support from Gavi Alliance, the World Health Organization (WHO), UNICEF, the UK Government and other health partners.

“The devastating floods and landslides which ravaged Sierra Leone throughout August have left the country dangerously vulnerable to water-borne disease outbreaks,” said Dr. Seth Berkley, CEO of Gavi Alliance. “Access to safe water and sanitation is limited, and the public health system, still recovering after the 2014 Ebola outbreak, is stretched. These lifesaving vaccines, alongside urgent support to improve safe water and sanitation, have the potential to prevent a cholera outbreak before it has the chance to bring more misery to a country that has already suffered enough.”

The decision to send cholera vaccines from the global stockpile was taken quickly on 31st August by the International Coordinating Group (ICG) for Vaccine Provision following the deployment of a WHO specialist to the country. The full quantity of the vaccine (1,036,300 doses for two rounds) is set to arrive in Freetown on 7th September through UNICEF’s global Supply Division.

WHO recommends that vaccination against cholera be considered in emergencies and other high-risk scenarios where there are increased threats of outbreaks, when combined with standard prevention and control measures for the disease. These measures include readiness to provide adequate testing and treatment, steps to ensure access to safe water and sanitation, and community mobilization to engage the public in preventing infection.

Sierra Leone’s last major cholera outbreak, in 2012, killed 392 people and infected more than 25,000 others.

Gavi, WHO, UNICEF and partners are working with the Ministry of Health and Sanitation to help plan and implement the campaign, which will make the vaccine available free-of-cost to disaster-affected populations, while supporting ongoing cholera prevention and preparedness.

::::::
 
UNICEF  [to 9 September 2017]
https://www.unicef.org/media/
Selected News Releases
Growing concern for nearly 1.4 million internally displaced people living in cholera ‘hotspots’ as outbreak spreads in northeast Nigeria
MAIDUGURI/DAKAR/NEW YORK 7 September 2017 – There is growing concern for the health and wellbeing of 1.4 million displaced people, including 350,000 children under the age of five, living in cholera ‘hotspots’ in northeast Nigeria, UNICEF warned today.
 
The outbreak occurs as ongoing violence and military efforts against insurgents in the region have displaced more than 1.7 million people and left over 3.6 million without adequate access to basic water services.
An estimated 28 people have died from cholera, while 837 are suspected to have been infected with the disease, including at least 145 children under the age of five. The outbreak was first identified in the Muna Garage camp for the displaced in Maiduguri, the state capital of northeast Nigeria’s Borno state. The outbreak spread quickly to as many as six other locations across the state. UNICEF and partners have rapidly scaled up their response to the cholera outbreak, as heavy rains multiply the risk of disease and malnutrition for conflict affected children.
 
“Cholera is difficult for young children to withstand at any time, but becomes a crisis for survival when their resilience is already weakened by malnutrition, malaria and other waterborne diseases,” said UNICEF Deputy Representative in Nigeria, Pernille Ironside. “Cholera is one more threat amongst many that children in northeast Nigeria are battling today in order to survive.”
 
A cholera preparedness plan has been in place since before the rains began. Religious leaders, community heads and local volunteers have been mobilised to encourage good hygiene practices and help refer suspected cases to health facilities. Water
is chlorinated at access points in the camps and across host communities in an effort to curb the spread of disease as the rainy season continues.
 
Since the outbreak was confirmed there has been a closely coordinated water, sanitation and hygiene (WASH) and health rapid response, driven by the Borno State Government with support from WHO, UNICEF and international non-governmental organisations, including the setup of a cholera treatment centre at the Muna Garage Camp.
 
As the impact of the rains is felt, UNICEF has also scaled up its nutrition and child health programmes across the three northeast Nigerian states most affected by conflict. So far this year, UNICEF has treated over 110,000 children suffering from severe acute malnutrition, distributed nearly 120,000 mosquito nets and provided emergency primary health care services to over three million people in these states. The response continues despite increased security concerns, reduced access because of floods and a heavily damaged health system.
 
Even in the face of a deadly cholera outbreak, the WASH sector remains critically underfunded. To date, UNICEF has only received 49% of funding needed to provide two million people with access to clean water, one of the main interventions that can protect children from deadly waterborne diseases and offer some protection against the threat of malnutrition.

::::::

Nigeria: MSF Scales Up Efforts to Contain Cholera Outbreak in Maiduguri
September 01, 2017
NEW YORK/MAIDUGURI, NIGERIA, SEPTEMBER 1, 2017—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is scaling up treatment and prevention to curb the spread of cholera in Maiduguri in Borno State, Nigeria.

::::::
::::::
 
Editor’s Note:
We will cluster these recent emergencies as below and continue to monitor the WHO webpages for updates and key developments.
 
MERS-CoV [to 9 September 2017]
http://www.who.int/emergencies/mers-cov/en/
DONS
Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia
6 September 2017
Between 13 and 30 August 2017, the National IHR Focal Point of Saudi Arabia reported 12 additional cases of Middle East respiratory syndrome coronavirus (MERS-CoV), including one death and, and one death from a previously reported case…

Yellow Fever  [to 9 September 2017]
http://www.who.int/csr/disease/yellowfev/en/
30 August 2017
African Health Ministers pledge firm actions against yellow fever
Victoria Falls, Zimbabwe,:  African health ministers currently meeting for the 67th Session of the World Health Organization (WHO) Regional Committee in Zimbabwe have agreed on ten priority actions to guide countries to eliminate Yellow Fever (YF) epidemics by 2026…
Introducing the Framework for implementing the Global Strategy to Eliminate YF on behalf of the WHO Regional Director for Africa, Dr Matshidiso Moeti,  the Acting Director for the WHO Health Emergencies Programme, Dr Zabulon Yoti informed the ministers that low YF vaccination rates, limited vaccine supply and emergency stockpile, inadequate implementation of the International Health Regulations (IHR 2005), climate change, rapid urbanization are some of the factors that have put over 440 million people at risk. The World Health Organization estimates that in one of the worst outbreaks in 2013, there were about 170 000 severe YF cases in Africa that led to about 60 000 deaths. The massive pre-emptive vaccination of over 30 million people during the recent outbreak in Angola and DRC was a measure that averted an epidemic that could have been of similar magnitude to that of 2013.
“Yellow Fever is still a serious public health risk within and outside the Region. With a single dose of YF vaccine per person, elimination of YF epidemics is indeed a quick public health gain. Country ownership and leadership is critical to protect people at risk through preventive and routine vaccination,” he said…

Zika virus  [to 9 September 2017]
http://www.who.int/csr/disease/zika/en/
No new announcements identified.
 
Sanofi Statement on Zika Vaccine License
Sep 1, 2017
On August 17, 2017, Sanofi Pasteur was informed by The Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services that they completed an assessment of all Zika-related projects they are funding and have decided to focus on a more limited set of goals and deliverables.

As a result of their review, Sanofi Pasteur has been notified of BARDA’s decision to “de-scope” its contract with Sanofi Pasteur to fund the manufacture and clinical development of an inactivated Zika vaccine and will limit its funding to a case definition and surveillance study as well as any activities required to advance our vaccine development to a point where development would be indefinitely paused but could be restarted if the epidemic re-emerges.
Consequently, Sanofi does not intend to continue development of, or seek a license from, the Walter Reed Army Institute of Research for the Zika vaccine candidate at this time.

We are proud of our contributions to the productive collaboration to date, which will result in significant contributions to science and to others who may continue pursuing licensure for an effective and safe Zika vaccine.

One of the ways Sanofi Pasteur will continue to contribute to the field of knowledge on Zika is by completing, with partial BARDA support, the ongoing case definition and surveillance study which will provide guidance on Zika epidemiology and diagnosis that can be applicable to any vaccine subsequently developed to prevent the disease.  The case-definition and surveillance study is currently being conducted in 4 countries—Colombia, Honduras, Mexico, and Puerto Rico—and we are looking to enroll 2,400 volunteers.

Given the evolving epidemiology of Zika, which has seen a profound reduction in the number of new Zika cases in the United States and around the world in 2017, as well as the results of the Phase I study, it was necessary to substantially extend our projected vaccine development timelines.  Therefore, we respect BARDA’s decision to re-purpose limited resources to meet their priorities.

In February 2016, Sanofi Pasteur urgently responded to the WHO’s declaration of a public-health emergency of international concern (PHEIC). In doing so, we assumed significant opportunity costs and delayed other internal pipeline priorities to lend our expertise to the Zika global public-health threat.  The epidemiology of the disease has changed significantly since that time, but we continue to believe that public-private partnerships are the right model to address these public health challenges and should continue to play a major role in response to emerging infectious diseases.

WHO & Regional Offices [to 9 September 2017]

WHO & Regional Offices [to 9 September 2017]

Seventieth session of WHO Regional Committee for South-East Asia
6 September 2017 — Dr Tedros outlined the priorities of WHO and several fast track initiatives during the transition period.

Highlights
Hurricane Irma: WHO taking measures to provide support
September 2017 – WHO country offices in the Caribbean are taking preventive measures to provide the necessary support to the authorities, and a team of infrastructure, engineering, and administrative specialists has been prepared to support the immediate assessment and response to the impact of countries located on the path of hurricane Irma.

A child’s search to treat kidney disease in Yemen
September 2017 – Accessing dialysis has always been tricky in Yemen, the poorest country in the Middle East. And now conflict has created additional challenges, with health facilities facing a shortage of supplies, and travel complicated by checkpoints and insecurity. In the midst of an economic crisis, it is exceptionally difficult for all patients to access the treatment they need.

Transforming primary care services in Kazakhstan
September 2017 – Kazakhstan is on track to achieve the global target of a 25% reduction in premature mortality from noncommunicable diseases by 2025. The main causes of years of life lost due to premature death in 2013 in Kazakhstan were ischaemic heart disease, cerebrovascular disease and self-harm.

::::::

Weekly Epidemiological Record, 8 September 2017, vol. 92, 36 (pp. 521–536)
:: Cholera, 2016
:: Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2017
:: The International Health Regulations (IHR) – 10 years of global public health security
 
::::::
 
WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Osun State distributes over two million Long Lasting Insecticide Treated Nets for malaria control. 08 September 2017
:: South Sudan launches the Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN)
:: WHO Intensifies Efforts to Contain Cholera Outbreak in Borno State  08 September 2017
:: WHO deploys Polio personnel to forestall disease outbreaks in Benue state communities affected by floods.  07 September 2017
:: WHO and the Carter Center supports the cash reward programme for reporting of Guinea Worm Disease in Tonj State, South Sudan 07 September 2017
:: South Sudan’s malaria toll highlights disease burden in war-torn nation  06 September 2017
:: Looking out for Acute Watery Diarrhoea in Somali region: A day in the life of a World Health Organization (WHO) surveillance officer in Ethiopia’s Somali region  05 September 2017
:: Sierra Leone to begin cholera vaccination drive in disaster-affected areas  05 September 2017
:: African Health Ministers pledge firm actions against yellow fever  04 September 2017

WHO Region of the Americas PAHO
:: Measles and Rubella Initiative Champion Award presented to PAHO (09/07/2017)
 
WHO South-East Asia Region SEARO
:: Prepare well to rapidly detect, respond to vector-borne diseases: WHO
:: Ministry of Health Maldives gets WHO Excellence in Public Health Award

WHO European Region EURO
:: Breakthrough for men’s health: WHO and experts kick off development of strategy and report 08-09-2017
For the first time, WHO is undertaking a strategy entirely focused on the health and well-being of men and boys. A group of experts from a range of fields and disciplines related to men’s health came together on 5 September 2017 at UN City in Copenhagen, Denmark, to launch the development of the strategy for the WHO European Region.

:: European leaders set new roadmap to achieve 2030 Agenda and improve 900 million people’s health and well-being 07-09-2017
Health leaders gather at the annual meeting of the WHO Regional Committee for Europe. In Budapest, Hungary on 11–14 September 2017 they will take decisions on health priorities that will have an impact on the health and well-being of about 900 million people in the WHO European Region, including in the European Union, central and eastern Europe, the Caucasus and central Asia.

:: Towards tobacco-free generations: emerging threats for children in the Region 06-09-2017
Several Member States in the WHO European Region are moving towards becoming “tobacco-free”, which means having a smoking prevalence of 5% or less. To achieve this, countries must address a number of tobacco-related issues that specifically impact children, and work to protect children from the harmful effects of tobacco.

::L Ukraine: 20% reduction in smokers since 2010 04-09-2017
The results of the Global Adult Tobacco Survey (GATS) recently released in Ukraine reveal a 20% reduction in the number of smokers over the past 7 years. Following WHO recommendations, Ukraine has strengthened its anti-tobacco legislation resulting in this reduction in the proportion of the population who smoke.

:: The Ashgabat Statement: Europe commits to staying malaria free 04-09-2017
The WHO European Region is marking an important step on the road from malaria control to malaria elimination, and then on to maintaining malaria-free status, with the launch of The Ashgabat Statement: Preventing the re-establishment of malaria transmission in the WHO European Region. The Statement is being formally presented on 4 September in Moscow, Russian Federation.

WHO Eastern Mediterranean Region EMRO
:: Effective preparedness for hajj 2017 (1438 H) pays off: no major public health events reported
3 September 2017, Makkah – The World Health Organization (WHO) today concluded a successful mission to Saudi Arabia to support the Ministry of Health in ensuring a safe hajj season. No disease outbreak or public health event of concern was reported among the nearly 2.4 million pilgrims visiting the holy sites during this year’s hajj, in spite of an increased number of pilgrims performing hajj this year.
WHO’s mission to Saudi Arabia was conducted as part of a range of activities undertaken by the Organization to support countries in ensuring effective implementation of the core public health capacities required under the International Health Regulations (IHR 2005) to prevent, detect and rapidly respond to any public health threat before it becomes an event of international concern. These activities are also outlined in the Regional Director’s roadmap which details a set of strategic actions to guide WHO’s work with Member States for the next five year…

CDC/ACIP [to 9 September 2017]

CDC/ACIP [to 9 September 2017]
http://www.cdc.gov/media/index.html

MMWR News Synopsis for September 7, 2017
:: Update: Increase in Human Infections with Novel Avian Influenza A(H7N9) Viruses During the Fifth Epidemic and Pandemic Preparedness — China, October 1, 2016–August 18, 2017
Avian influenza A(H7N9) viruses remain a pandemic concern. The fifth annual epidemic of Asian Lineage Avian Influenza A(H7N9) Viruses in China is marked by extensive geographic spread in poultry and in humans. The number of human infections reported in the fifth epidemic is almost as many as were reported during the previous four epidemics combined. The increased number of human infections appears to be associated with wider geographic spread and higher prevalence of Asian H7N9 viruses among poultry rather than any increased incidence of poultry-to-human or human-to-human spread. Human infections with Asian H7N9 viruses from poultry are rare, and no efficient or sustained human-to-human transmission has been detected. Among all influenza viruses assessed using CDC’s Influenza Risk Assessment Tool, the Asian H7N9 virus is ranked as the influenza virus with the highest potential pandemic risk. Continued vigilance is important to identify changes in the virus that have epidemiologic implications, such as increased transmission from poultry to humans or transmission between humans.

Announcements

Announcements
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 9 September 2017]
http://cepi.net/
[Undated]
Call: Platform technologies to enable rapid vaccine development for epidemic prone infections
CEPI is pleased to announce its second funding opportunity for the development of vaccines against epidemic infectious diseases.
In this two-step call, CEPI asks for submission of proposals for vaccine platform technologies that enable rapid vaccine development, rapid scale up, and quick time to immunity for reactive use in outbreaks of novel or previously unrecognised viruses. Proposals can include new platforms with the potential for rapidly making a vaccine using materials generally regarded as safe (GRAS), or those compressing the time of an existing (proven) platform to make it more responsive in an unknown threat situation. During the proposed project period, we encourage developers to target the following timelines:
Target a 16-week timeframe from identification of antigen to product release for clinical trials
Target a 6-week timeframe from administration of first dose to achievement of clinical benefit (i.e. immune response likely to result in clinical benefit)
Produce 100,000 vaccine doses within 8 weeks to impact an emerging outbreak (i.e. from Go-decision to scale-up to production, fill, finish, and release)
Timeline
Deadline for submission of step 1 proposals: 4 p.m. CEST 17 October 2017
Call text for proposals on platform technology PDF FORMAT – 272KB Download

EDCTP    [to 9 September 2017]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

European Medicines Agency  [to 9 September 2017]
http://www.ema.europa.eu/ema/
04/09/2017
Reporting side effects of medicines
EMA launches survey to assess whether patients and doctors are aware of the arrangements for reporting of side effects …
 
FDA [to 9 September 2017]
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
What’s New in Biologics
Influenza Virus Vaccine for the 2017-2018 Season
Updated: 9/7/2017
 
Fondation Merieux  [to 9 September 2017]
http://www.fondation-merieux.org/
September 5, 2017, Bamako, Mali
First day of school for the BAMS training in medical applied biology
On 1 October 2007[?2017?], the first year of students – professionals of biological analysis, arrived at the Charles Mérieux Center for Infectious Disease in Bamako in order to follow the new qualified laboratory technicians training: BAMS.
The Mérieux Foundation knows that the improvement of the quality in public health needs the strengthening of capacities in medical biology: it has decided, in partnership with ESTBB, to create the BAMS training.
16 laboratory technicians selected among 85 candidates will follow until May 2008 theoretical and practical teaching in the fields of immunology, biochemistry, bacteriology, parasitology, virology and molecular biology. The teachers of these courses are Malian and French.
The technicians chosen for this first year of BAMS work in different national health centres of reference in Mali and Burkina Faso. The Ministry of Health in Mali accepted that the technicians follow the training because the health professionals were committed to return to work in their original laboratories in order to contribute to the quality of the public health.
 
Gavi [to 9 September 2017]
http://www.gavi.org/library/news/press-releases/
05 September 2017
Sierra Leone to begin cholera vaccination drive in disaster-affected areas
More than 1 million doses of Gavi-funded cholera vaccines heading to Sierra Leone after severe flooding and landslides.
[See Cholera above for more detail]
 
IVI   [to 9 September 2017]
http://www.ivi.int/
September 4, 2017
IVI Hosts 17th International Vaccinology Course in Seoul on September 4-8
:: Aeras Chief Medical Officer Dr. Ann Ginsberg delivers closing plenary speech on TB vaccine development; Korea University Prof. Woo-joo Kim to address Vaccine Preparedness and Response to Emerging Infectious Diseases
:: 112 participants from 19 countries including trainees participate in this year’s event hosted jointly by IVI, KOHI
:: 35 experts from international agencies, research institutions, universities, industry and non-profit organizations, including IVI, WHO and U.S. NIH serve as faculty members
 
MSF/Médecins Sans Frontières  [to 9 September 2017]
http://www.doctorswithoutborders.org/news-stories/press/press-releases
Press release
Nigeria: MSF Scales Up Efforts to Contain Cholera Outbreak in Maiduguri
September 01, 2017
NEW YORK/MAIDUGURI, NIGERIA, SEPTEMBER 1, 2017—The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is scaling up treatment and prevention to curb the spread of cholera in Maiduguri in Borno State, Nigeria.
 
NIH  [to 9 September 2017]
http://www.nih.gov/news-events/news-releases
September 7, 2017
NIH awards nearly $100 million for Autism Centers of Excellence program
— Program supports large research projects aimed at understanding and developing interventions for autism spectrum disorder

NCI’s Douglas R. Lowy and John T. Schiller to receive 2017 Lasker Award
September 6, 2017 — Scientists honored for their research leading to the development of HPV vaccines
[See Milestones above for more detail]

Zika virus selectively infects and kills glioblastoma cells in mice
September 5, 2017 — Researchers describe the impact of ZIKV on glioblastoma cells in human tissue samples and mice

Drug combination reduces risk of HIV infection among teen males
September 5, 2017 — NIH-funded study suggests PrEP therapy, approved for adults, is safe for youth.
 
PATH  [to 9 September 2017]
http://www.path.org/news/index.php
Press release | September 08, 2017
PATH and Walter Reed Army Institute of Research announce largest-ever controlled malaria infection study
Study in adult US volunteers to investigate which changes in the RTS,S malaria vaccine candidate regimen increase protection the most

Press release | September 06, 2017
PATH boosts leadership in developing and introducing urgently needed vaccines
PATH’s Center for Vaccine Innovation and Access attracts top global talent and additional $120 million investment from the Bill & Melinda Gates Foundation
[See Milestones above for more detail]
 
 
Wellcome Trust  [to 9 September 2017]
https://wellcome.ac.uk/news
News / Published: 4 September 2017
Wellcome joins £52 million global drive on antibiotic resistance
Wellcome is committing up to £1 million as part of a £52 million (€56.5m) global pledge to tackle antibiotic resistance.
Latest funding for the Global Antibiotic Research and Development Partnership (opens in a new tab) (GARDP) was announced today by the German government.
Other countries and foundations pledging funds include the Netherlands, Switzerland, South Africa, Luxembourg and the UK government.
Jeremy Farrar, Wellcome’s Director, said: “We must all work together to address the deadly threat of drug-resistant infections, which already kill 700,000 people a year. Wellcome is delighted to work with Germany and other partners to ensure communities around the world are better protected against this and other serious health threats.”…
 
::::::
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 9 September 2017]
http://www.dcvmn.org/
25 September 2017 to 28 September 2017
DCVMN Annual General Meeting
Seoul / Korea

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

 
Ebola research agenda
Infectious Diseases Data Observatory (IDDO)
Help design a collaborative research agenda to inform and inspire analyses using data from the Ebola data sharing platform. You can contribute your ideas on research priorities which address knowledge gaps with new evidence to improve patient care and outbreak response.
Construction of the Ebola data sharing platform is currently under way with available clinical and laboratory data, and will later include epidemiological data.
We want to hear from you, the research, health and humanitarian communities, about what the priority research questions are. Please download our Ebola Data Sharing Platform: Draft Research Agenda for Public Consultation and contribute to the development of a research agenda which maximises the impact of available data.
 
Massive Ebola data site planned to combat outbreaks
Nature | News 04 September 2017
Amy Maxmen
An international partnership seeks African leadership to organize information about the disease.
More than 11,000 people died when Ebola tore through West Africa between 2014 and 2016, and yet clinicians still lack data that would enable them to reliably identify the disease when a person first walks into a clinic. To fill that gap and others before the next outbreak hits, researchers are developing a platform to organize and share Ebola data that have so far been scattered beyond reach.
The information system is coordinated by the Infectious Diseases Data Observatory (IDDO), an international research network based at the University of Oxford, UK, and is expected to launch by the end of the year. At a meeting to discuss Ebola on 7–9 September in Conakry, Guinea, the team heading the platform will seek input from West African scientists, health officials and advocacy groups.
“We are looking for West African leadership in this initiative,” says Laura Merson, associate director of the IDDO.
Africans must be involved in the platform’s creation so that they can not only use the existing data, but also improve their capacity to conduct research during future outbreaks, says John Amuasi, an infectious-diseases researcher at the Kumasi Centre for Collaborative Research in Tropical Medicine in Ghana and a member of the platform’s steering committee. A true partnership would also lessen the general public’s mistrust of scientists, he adds….

Journal Watch

Journal Watch

   Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

American Journal of Tropical Medicine and Hygiene – Volume 97, Issue 3, 2017

American Journal of Tropical Medicine and Hygiene
Volume 97, Issue 3, 2017
http://www.ajtmh.org/content/current

Editorials
The Fogarty International Center is Essential to Global Health Security
Author: John Edward Porter
https://doi.org/10.4269/ajtmh.17-0597

Let’s Eliminate Diseases, Not Institutes: The Case for the Fogarty International Center
Authors: Philip J. Rosenthal, Karen A. Goraleski, N. Regina Rabinovich and Patricia F. Walker
https://doi.org/10.4269/ajtmh.17-0601

Congressman John E. Fogarty: A Champion for Global Health
Author: Mary Fogarty McAndrew
https://doi.org/10.4269/ajtmh.17-0612

Advocating for the Fogarty International Center: An Unsung Hero for Global Health Research and Development
Author: Jamie Bay Nishi
https://doi.org/10.4269/ajtmh.17-0611

Classification and Visualization of Physical and Chemical Properties of Falsified Medicines with Handheld Raman Spectroscopy and X-Ray Computed Tomography

American Journal of Tropical Medicine and Hygiene
Volume 97, Issue 3, 2017
http://www.ajtmh.org/content/current

Articles
Classification and Visualization of Physical and Chemical Properties of Falsified Medicines with Handheld Raman Spectroscopy and X-Ray Computed Tomography
Authors: Tomoko Kakio, Naoko Yoshida, Susan Macha, Kazunobu Moriguchi, Takashi Hiroshima, Yukihiro Ikeda, Hirohito Tsuboi and Kazuko Kimura
https://doi.org/10.4269/ajtmh.16-0971
Analytical methods for the detection of substandard and falsified medical products (SFs) are important for public health and patient safety. Research to understand how the physical and chemical properties of SFs can be most effectively applied to distinguish the SFs from authentic products has not yet been investigated enough. Here, we investigated the usefulness of two analytical methods, handheld Raman spectroscopy (handheld Raman) and X-ray computed tomography (X-ray CT), for detecting SFs among oral solid antihypertensive pharmaceutical products containing candesartan cilexetil as an active pharmaceutical ingredient (API). X-ray CT visualized at least two different types of falsified tablets, one containing many cracks and voids and the other containing aggregates with high electron density, such as from the presence of the heavy elements. Generic products that purported to contain equivalent amounts of API to the authentic products were discriminated from the authentic products by the handheld Raman and the different physical structure on X-ray CT. Approach to investigate both the chemical and physical properties with handheld Raman and X-ray CT, respectively, promise the accurate discrimination of the SFs, even if their visual appearance is similar with authentic products. We present a decision tree for investigating the authenticity of samples purporting to be authentic commercial tablets. Our results indicate that the combination approach of visual observation, handheld Raman and X-ray CT is a powerful strategy for nondestructive discrimination of suspect samples.